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N-methoxybenzylphenethylamines (NBOMe) were first synthesised and published in 
Ralf Heim’s thesis in 2003,1 detailing the selectivity of these compounds towards 
serotonin receptors (5-HT2A). This thesis details the full synthesis of seven 
phenethylamines (10 – 93 % yield as their hydrochlorides) and their transformation 
into the corresponding NBOMe’s (27 – 74 % yield as their hydrochlorides) with full 
characterisation to compare against literature. The synthesis of 21 novel derivatives 
(containing either a 3-pyridylmethyl-, 5-fluoro-3-pyridylmethyl- or 4-methoxy-3-
pyridylmethyl- moiety) was achieved via reductive amination (3 – 18 % yield as their 
hydrochlorides), which were evaluated in Signal Amplification By Reversible 
Exchange (SABRE) Hyperpolarisation experiments in their free-base forms. A GC-MS 
method has be developed and achieves separation of eight NBOMe’s in 11 minutes 
with Limits of Detection (LoD) and Quantification (LoQ) of 6.2 – 10.8 µg mL-1 and 18.8 
– 32.6 µg mL-1 respectively. The developed method has been validated against 
simulated blotters impregnated with the NBOMe’s and directly compared against ATR-
FTIR and presumptive (Marquis and Lieberman) colour tests.  
 
SABRE Hyperpolarisation was explored using the 3-pyridylmethyl-, 5-fluoro-3-
pyridylmethyl- or 4-methoxy-3-pyridylmethyl-containing derivatives, and achieved 1H 
and enhancements, via a low field (60 MHz) NMR, of 2x – 192x – where the best 
enhancement was observed in the 25B-NBOMe derivative where the 2-
methoxybenzyl- group was replaced with a 4-methoxy-3-pyridylmethyl- moiety. These 
preliminary results indicate the potential for further development of these compounds 
as possible agents for medical imaging.  
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1 Chapter 1 - Introduction 
1.1 Misuse of Drugs Act (1971) 
In the United Kingdom (UK), the regulation of drugs and illegal substances is controlled 
through the Misuse of Drugs Act (1971), the Misuse of Drugs Regulations (2001) and 
their subsequent amendments, which makes new laws with respect to the dangerous 
or otherwise harmful drugs and related matters. The act repealed the whole of the 
Drugs (Prevention of Misuse) Act 1964, and the Dangerous Drugs Acts of 1965 and 
1967.2 The UK legislation before 1971 was fragmented and inflexible due to the 
constantly changing nature of drugs. For example, a drug, which may have never been 
abused previously, may become a popular drug of abuse in a very short time period. 
In this circumstance, it was difficult for the UK to bring such a drug under the 
restrictions of the original Dangerous Drugs Act unless it was recommended to, or 
appeared to be recommended to, by the United Nations Narcotics Commission.2 
 
Figure 1 – Chemical structures of class A drugs; 3,4-
methylenedioxymethamphetamine (MDMA, 1), methamphetamine (2), lysergic acid 
diethylamide (LSD, 3), cocaine (4), N,N-dimethyltryptamine (DMT, 5) 
 
Unless an appropriate license is held, it is now illegal for a person to possess a 
controlled drug, with or without intent to supply (with or without exchange in currency), 
including within a property. Such substances can be separated into different classes 
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(A, B, C) each with different penalties associated with them (Table 1). Class A, being 
the most dangerous, has the highest penalties (examples of class A’s in Figure 1) and 
Class C the least, but one can possess a Class A drug as long as they have a 
prescription. However, administration of the drug is done under close scrutiny by a 
medical professional.  
 
Substances can also be controlled by the controlled substances act, which is part of 
the Comprehensive Drug Abuse Prevention and Control Act (1970). The Drug 
Enforcement Administration (DEA) divided substances into schedules based on 
potential for abuse and addictiveness, as well as whether or not the substance has 
any legitimate medicinal uses.3 There are three factors on which the substance is 
scheduled; the potential of abuse, accepted medical use (used as a treatment in the 
US), potential of addiction. Table 2 summarises the different schedules.4 
 
Table 1 - Penalties associated for possession and supply of controlled drugs4 
Offence Court Class A Class B Class C 
Possession 
Magistrates 
6 months / 
£5000 fine 
3 months / 
£2500 fine 
3 months / 
£250 fine 
Crown 
7 years / 
unlimited fines 
5 years / 
unlimited fines 






6 months / 
£5000 fine 
6 months / 
£5000 fine 
3 months / 
£2000 fine 
Crown 
Life / unlimited 
fine 
14 years / 
unlimited fine 
14 years / 
unlimited fine 
 
There are some crossovers between class A substances and schedule 1 substances. 
Compounds such as LSD and DMT appearing on both lists. There are also differences 
with substances such as cocaine appearing as a class A drug but being placed into 
schedule 2, whereas cannabis is a class B schedule 1 drug. Some drugs of abuse 
(including the prior mentioned) have been listed in Table 3.  
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Table 2 – List of schedules for controlled substances 





Schedule 1 High None Not safe to use 









Schedule 3 Medium Yes 





Schedule 4 Moderate Yes 
The drug may 
cause moderate 
mental or physical 
addiction 
Schedule 5 Lowest Yes 
The drug may 





Table 3 – Exemplar list of drugs with their associated class and schedule regulations 
 Class Schedule 
Amphetamine B 2 
Anabolic steroids C 3 
Benzodiazepines C 4 
Cannabis B 1 
DMT A 1 
Ecstasy A 1 
Heroin A 2 
Ketamine B 3 
LSD A 1 
Methadone B 2 
Morphine A 2 
NBOMe A 1 
Pyrovalerone C 5 
2C-series A 1 
 
The Misuse of Drugs Regulations (2001) were produced in order to allow the lawful 
production and possession of controlled substances for legitimate circumstances. This 
regulation covers the administration, possession, destruction and disposal of these 
substances.5 The Misuse of Drugs Act (1971) was amended in 2005 to review the 
classification system of controlled substances and amendments were made to 
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schedule 1. Changes were also made to policing powers relating to drugs and 
sentencing punishments.6    
 
Phenethylamine (6, Figure 2) has a basic structure that can elicit stimulant and/or 
hallucinogenic properties, which can be differentiated as catecholamines (7), 
amphetamines (8), synthetic cathinones (9), and many other drugs.7 These are 
typically composed of a benzyl ring with a terminal amine separated by an ethyl chain. 
However, the 2C series (10) possess dimethoxy groups in the two and five position, 
with the lipophilicity of the group in the four position can alter its pharmacological and 
clinical effects, creating a vast array of derivatives.8 These can include halogens, alkyl, 
thiol and nitro groups but the most popular within the recreational scene is with 
bromine, 2,5-dimethoxy-4-bromophenethylamine (2C-B). This drug first appeared on 
the illicit market scene in 19809 and then gained increasing popularity in the 1990’s, 
when it was sold in so-called smart shops.10 All of the 2C family (11) is currently 
legislated in the Class A category meaning they are illegal to produce, supply or 
possess. 
 
Figure 2 - Chemical structures of phenethylamine (6), dopamine (7), amphetamine (8), 
cathinone (9), “2C-series” (10, X = halogen, alkyl, thiol, nitro) and NBOMe series (11, 
X = halogen, alkyl, thiol, nitro) 
 
The 2C family is the parent for the N-methoxybenzyl (NBOMe, 11) analogues, which 
fall into the phenethylamine “catch-all” clause meaning they are also Class A drugs. 
This class of drugs were first synthesised in 2003 by Ralf Heim as part of his PhD 
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thesis,1 and deemed a hazard to public health and safety later on.11 The Drug 
Enforcement Administration placed 25I-NBOMe, 25B-NBOMe and 25C-NBOMe into 
Schedule 1 of the Controlled Substances Act on 10 October 2013.12 The nature of the 
drug is to mimic LSD as it stimulates the 5-HT2A receptor, therefore blotter papers 
containing 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine 
(25I-NBOMe) appeared on the designer drug market beginning 201113 and since then 
numerous derivatives have been seized including: 2-(2,5-dimethoxy-4-methylphenyl)-
N-(2-methoxybenzyl)ethanamine (25D-NBOMe, 11a, X = Me), 2-(4-ethyl-2,5-
dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine (25E-NBOMe, 11b, X = Et) and 




24 | P a g e  
 
1.2 N-Methoxybenzylphenethylamines (NBOMe) 
Ralf Heim first synthesised the N-methoxybenzyl phenethylamine (NBOMe) series of 
psychoactive substances and determined them to be potent serotonin (5-HT) agonists. 
This was previously known due to the 2C series also showing agonistic properties 
towards this receptor, which bind the 5-HT receptor to cause a response. Specifically, 
this compound targets the 5-HT2A receptor that appears to play a key role in a number 
of disease states. These disease states include addiction,17 schizophrenia,18 
obsessive compulsive disorder,19,20 depression,21,22 pain,23 inflammation,24 migraine,25 
and cluster headaches,26 and in the manifestation of mystical/religious-type 
experiences as well as in altered states of consciousness.18, 27 
 
Initially, N-substituted phenethylamines were thought to be inferior compared to the 
parent phenethylamines because early studies involving N-alkylation with simple 
substituents (e.g. methyl, ethyl, propyl) produced compounds with significantly 
diminished activity.28 Therefore, it was surprising when Heim discovered that N-
benzyl, and specifically N-(2-methoxy)benzyl, substitution dramatically improved both 
binding affinity and functional activity and in vivo 5-HT2A activation compared to simple 
phenethylamines such as 4-iodo-2,5-dimethoxyphenethylamine (2C-I).1, 29 
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1.2.1 NBOMe Synthesis 
NBOMe’s are synthesised with a reductive amination (Scheme 1) of a 2C series 
compound to form a potent hallucinogen with high abuse potential,30 powerful 
psychoactive properties and stimulating effects (Scheme 2).31  
 
Scheme 1 - General reaction scheme of NBOMe synthesis (X=F, Cl, Br, I), (1 eq. 
triethylamine (TEA) required if phenethylamine is a hydrochloride salt) 
 
In 2003, preliminary explorations led to the conclusion that N-2-methoxybenzyl 
substitution, not only of phenylethylamines but also phenylisopropylamines, 
tryptamines and 3-(2-aminoethyl)-(1H,3H) quinazoline-2,4-diones related to the typical 
5-HT2 receptor antagonist ketanserin (12, Figure 3), results in particularly high 
affinities for 5-HT2A receptors. 1 The pharmacophore shown in Figure 4 highlights the 
similarities of functional groups.  
 
 
Figure 3 - Chemical structure of the 5-HT2 receptor antagonist Ketanserin (12) 
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Scheme 2 - General reaction scheme for final compound synthesis (R1 = Me, Cl, F; X = F, Cl, Br, I, Me, Et, NO2). A) Synthetic route 
of 31, HMTA, TFA, reflux, 15 h, 55 %; b) nitromethane, ammonium acetate, AcOH, reflux, 4 h, 34 %; c) LiAH4, THF, RT, 3 h, 34%; 
synthetic route of 34, POCl3, N-methylformanilide, RT, 2 h, 97 %; b) nitromethane, ammonium acetate, acetic acid, reflux, 3 h, 66 %; 
c) LiAH4, THF, RT, 3 h, 14 %; B) Synthetic route of 41, acetyl chloride, aluminium chloride, DCM, RT, 1 h, 83%; (b) KOH, triethylene 
glycol, hydrazine hydrate (40 %), 150°C, 4 h, 85%; (c) iodomethane, KOH, DMSO, 40°C, 1 h, 95 – 99%; (d) tin (IV) chloride, 
dichloromethyl methyl ether, anhydrous DCM, 0°C – RT, 1 h, 83%; (e) nitromethane, ammonium acetate, 100°C, 4 h, 29%; (f) LiAH4, 
anhydrous THF, RT, 3 h, 50%; C) Synthetic route of 28, Br2, AcOH, RT, 5 min, 49%; synthetic route of 47 a) phthalic anhydride, 
reflux, 6 h, 72 %; b) iodine monochloride, AcOH, 40 °C, 1 h, 76 %; c) hydrazine hydrate, IPA, reflux, 12 h, 10 %; synthetic route of 
48, HNO3, AcOH, 0 °C, 1 h, 66% 





Figure 4 - Pharmacophore of both 11 and 12 highlighted in red 
 
In NBOMe’s, substitution patterns at the ortho position of the benzyl group showed 
similar potencies with an oxygen, however, the range of substituents remains 
unknown. It is difficult to rationalize the molecular basis of receptor affinity and 
functional potency and efficacy of this interesting family of drugs even though a π-π 
stacking interaction and a hydrogen bond, both involving the benzyl moiety, have been 
invoked as partial explanations.32, 33, 34 Also, the pharmacological study of an 
expanded set of analogues is likely to reveal the causes of their suspected toxicity and 
uncover new substances with therapeutic potential.35 
 
A part that is not well recognised in medicinal chemistry is the halogen bonding 
associated with the protein backbone. These can be as strong as hydrogen bonding, 
whilst also having an almost neutral net enthalpy change. The strength of the bonding 
is due to the electronegativity associated with the halogen in use. A recent example of 
compounds that may merit analysis in this context are cytotoxic oxadiazoles in which 
replacement of a methyl group by a chlorine or bromine atom results in an at least 
fourfold increase in potency which is greater for bromine than for chlorine.36 The 
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presence of bromine could potentially lead to increasing 5-HT2A receptor affinity thus 
increasing the potency and the ability to study the differences in their actions. 25B-
NBOMe derivatives were the primary focus of Tiraoegui as the affinities associated 
with 5-HT2A was higher than most 25X related compounds (X = F, Cl, I, Me, NO2) with 
Et being an exception.37 
 
Tiraoegui et al.35 investigated reductive amination (Scheme 3) with aryl-brominated 
compounds, as these derivatives of NBOMe’s have not been described (tryptamine 
derivatives also included) in literature. An “indirect” procedure was used by reacting 
the amine and aldehyde to generate the imine. After being left to stir overnight, addition 
of sodium borohydride (NaBH4) was the reducing agent used in situ in methanol to 
form the substituted NBOMe derivatives. The two examples of halogenated 2-
oxygenated NBOMe derivatives are 2-(4-bromo- 2,5-dimethoxyphenyl)-N-(4-bromo-2-
methoxyphenylmethyl)ethanamine (13a) and 2-(4-bromo- 2,5-dimethoxyphenyl)-N-(5-
bromo-2-methoxyphenylmethyl)ethanamine (13b), which exhibited submicromolar 
affinities (against the antagonist [3H] ketanserin) for human 5- HT2A receptors with pKi 




Scheme 3 – Preparation of 2-aryl-N-substituted benzylethanamines. a) MeOH, 12 h; 
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1.2.2 Structure-Activity relationship between NBOMe derivatives and the 5-HT 
receptor family 
Data suggests that drugs of the 2C-class interact effectively with serotonin receptors, 
most of which act as 5-HT2A receptor agonists. Typically, a 2C-class substance carries 
a lipophilic substituent in the para-position (relative to the side chain), which 
contributes to further enhance 5-HT2A affinity and partial agonistic action.38 The most 
active compounds identified to date possess an ether, alkylthio, alkyl, or halogen group 
at this position and their potency increases in the aforementioned sequence.39, 40 The 
results retrieved from SAR studies suggest that N-substitution of common 
phenethylamines with short alkyl substituents (methyl or ethyl groups) considerably 
decreases the binding affinity for serotonin receptors compared to the unmodified 
compounds (Figure 5).  
 
Figure 5 – SAR diagram of an NBOMe; green indicates halogen bonding when X = Br, 
Cl, F, I; blue indicates π-π stacking; purple indicates H bond acceptor groups and 
yellow indicates H bond donor/acceptor group 
 
However, the addition of an N-benzyl moiety increases the affinity and potency. 
Braden et al.41 illustrated this by performing a radio ligand binding assay which 
monitors the drugs ability to displace either [125I]4-iodo-2,5-
dimethoxyphenylisopropylamine (DOI) and [3H]ketanserin in different membranes. By 
adding an N-benzyl group to 2,5-dimethoxy-b-phenethylamine (2C-H), the binding 
affinity increased 13-times.41 The addition of an N-(2-methoxy) benzyl, or N-(2-
hydroxy) benzyl, group to 2C-H led to 190- and 82-fold increases in affinity, 
respectively. Moreover, the latter substances displayed high selectivity (> 1000-fold) 
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for 5-HT2A receptors over 5-HT1A and moderate selectivity (up to 35-fold) for 5-HT2A 
over 5-HT2C. 
 
Heim1 was the first to investigate the pharmacological properties of the NBOMe series. 
25C-NBOMe acts as a potent 5-HT2A receptor’s partial agonist. 11C radiolabelled form 
of 25C-NBOMe has been studied as a potential ligand to map the distribution of 5- 
HT2A receptors in the brain by positron emission tomography (PET).42 This drug has a 
nanomolar affinity to the 5-HT2A receptor displaying an agonistic binding affinity of 2.89 
± 1.05 nM in vitro,43 thus it has been characterized as “superpotent” by Braden et al.32 
It is pharmacologically active even at considerably small submilligram doses.15 
 
Moreover, Halberstadt and Geyer29 studied the effects of 25I-NBOMe on the head 
twitch response (HTR) that is induced by activation of 5- HT2A receptor in rats and 
mice and is widely used as a behavioural proxy for hallucinogen effects in humans. 
25I-NBOMe displayed 14-fold higher potency than 2C-I. The findings suggest that 
phenethylamine hallucinogens induce the HTR by activating 5-HT2A receptors and that 
25I-NBOMe is a highly potent derivative of 2C-I, which is in accordance to previous in 
vitro findings suggesting that N-benzyl substitution increases 5-HT2A affinity. 
 
25I-NBOMe is active from 50 – 250 µg but dosing ranges from 500 – 800 µg for 
insufflation and has a 6 h duration.29 However, what all the NBOMe’s have in common 
is that if the dosing is not correct, fatalities can occur.44 This is primarily due to the user 
not knowing what substance they are taking, they can be passed on as research 
chemicals, herbal remedies, bath salts, etc., without proper labelling as to what the 
product contains along with concentrations of substances encased. The effects of 25I-
NBOMe intoxication can lead to tachycardia, hypertension, agitation and aggression, 
visual and auditory hallucinations, seizures, hyperpyrexia, clonus, elevated white 
blood cell count and metabolic acidosis.44 
 
The docking process involves the prediction of a ligand conformation and orientation 
within a target’s binding/active site. Subsequent calculations calculate structural 
factors that determine the correct positioning within the active site.45 Multiple steps are 
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taken with each step increasing the degree of complexity,46 due to the complex issues 
involved with biological recognition and the ability to simulate these on a computer. 
 
There are currently seven 5-HT family receptor types with 14 known subtypes 
integrated within. 13 of these belong to the G protein-coupled receptor (GPCR), with 
5-HT3 classified an ion channel.47, 48, 49 Among the seven subclasses (5- HT1–7) of 
serotonin receptors, 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT3 are especially well known for 
their association with addictive substances, such as cocaine, amphetamine, 
methamphetamine, MDMA (ecstasy), morphine/heroin, cannabis, alcohol, and 
nicotine.50  
 
Wang et al.51 reported the crystal structures of the human 5- HT1B receptor bound to 
its agonists ergotamine (ERG) and dihydroergotamine. Their structures revealed that 
these ligands shared similar binding modes in 5-HT1B, occupying the orthosteric pocket 
and an extended binding pocket close to the extracellular loops. They also compared 
the structure with the 5-HT2B receptor and found that the 5-HT1B receptor displayed a 
3 Å outward shift at the intracellular end of 6th trans-member helices (TM6), resulting 
in a more open extended pocket that may explain the subtype selectivity. To 
investigate the structural basis for biased signalling, Wacker et al.52 reported the 
crystal structure of the human 5-HT2B receptor bound to ERG (Protein Data Bank 
(PDB) entry: 4IB4, resolution: 2.7 Å) and compared it with the 5-HT1B/ERG structure. 
These crystal structures provide a comprehensive structural basis for understanding 
the receptor–ligand interactions of the 5-HT family subtypes.  
 
Wang et al.53 researched molecular docking, molecular dynamics simulation and 
systems pharmacology analysis with the serotonin receptor family. Previous models, 
protocols and parameters were used for these studies54-57 to view the binding pockets 
of all of the receptor groups. Through molecular docking and simulations, 
commonalities between each subtype was identified and the uniqueness of the 
residues which contribute to the selectivity of each receptor. Table 4 shows the key 
residues involved within the 5-HT2 family biding pockets, with the bold residues playing 
being the grantor between the selectivity. 
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Table 4 – Key residues involved in the binding pocket of 5-HT2 receptors 
No. Location 5-HT2A 5-HT2B 5-HT2C 
1 3 x 32 Asp155 Asp135 Asp134 
2 3 x 33 Val156 Val136 Val135 
3 3 x 36 Ser159 Ser139 Ser138 
4 5 x 39 Phe234 Phe217 Phe214 
5 5 x 40 Val235 Met218 Val215 
6 5 x 43 Gly238 Gly221 Gly218 
7 5 x 46 Ser242 Ala225 Ala222 
8 6 x 48 Trp336 Trp337 Trp324 
9 6 x 51 Phe339 Phe340 Phe327 
10 6 x 52 Phe340 Phe341 Phe328 
11 6 x 55 Asn343 Asn344 Asn331 
12 7 x 35 Asn363 Glu363 Asn351 
13 7 x 38 Val366 Val366 Val354 
14 7 x 42 Tyr370 Tyr370 Tyr358 
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1.2.3 NBOMe Metabolism 
The study of the metabolism of 2C-B (28, Scheme 4) has been extensively researched 
using rat and mice models, as well as human urine. The studies showed the major 
metabolic pathway to be deamination (Phase I, 14a) followed by oxidation of the 
aldehyde to the corresponding carboxylic acid (Phase II, 14b). The minor metabolic 
pathway 2C-B is O-demethylation (Phase I, 15a) of the parent compound, followed by 
acetylation (Phase II, 15b).58  
 
Scheme 4 – Major and minor metabolic pathways processes of 2C-B 
 
When looking at the metabolism of the NBOMe compounds, a precise mechanism of 
action is difficult due to an increased number metabolic routes. For 25B-NBOMe, 
Boumrah et al.59 identified 21 Phase I and II metabolites only in vitro after incubation 
with human liver microsomes and cofactors for CYPs and glucuronyl transferases. 
Caspar et al.30 have identified 35 Phase I and 31 Phase II metabolites present in 
human and rat urine, due to several being combined metabolic reactions or isomers 
of previous ones. 
 
Caspar et al.60 previously studied the metabolism process of 25I-NBOMe. A total of 68 
metabolites found, 37 of those being phase I and 30 being phase II. In summary, O-
demethylation seemed to be the main metabolic pathway and N-
demethoxybenzylation only a minor one in humans and rats.60 
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All phase II pathways could be proposed for both species with the exception of the N-
acetylation, which was observed only in rats after the high dose. Again, the relative 
abundance also of the different conjugates varied between the species, but this was 
only a rough estimation as already discussed above.60 
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1.2.4 NBOMe Prevalence 
Despite NBOMe’s being synthesised in 2003, recreational use of these drugs did not 
occur until 2010 and case reports followed in 2013 after David Nichol’s research on 
the drug in 2008. This included creating a radio-labelled form of 25I-NBOMe for use 
as a high affinity, traceable 5- HT2A ligand, applicable to positron emission tomography 
and other research purposes.61 However, by 2010, 25I-NBOMe began to appear on 
the internet.62 Recreational users then went online to post their experiences on 
EROWID, an online psychoactive drug and plant library, which defined NBOMe’s as 
“the defining psychedelics of 2013”. 
 
25I-NBOMe, described as the prototype, is part of the expanded class of NBOMe’s 
with the defining group being the addition of 2-methoxybenzyl moiety to the backbone 
of the phenethylamine. This addition increases the affinity by up to 16 times compared 
to its counterpart, 2C-I.  
 
Laskowski et al.63 showcases an example of the prevalence of NBOMe’s with two case 
studies, both being teenagers, who claimed to ingest 25I-NBOMe. The patient in the 
first case study self-administered a “25I-NBOMe” blotter, followed by a seizure within 
30 minutes. After being taken to the emergency department (ED), a second seizure 
occurred minutes after being admitted which was resolved with lorazepam. Serum and 
urine obtained (7 and 9 hours post admission respectively) contained 25C-NBOMe at 
>0.025 ng mL-1 and 1 ng mL-1 respectively. 25I-NBOMe was not detected. The patient 
in the second case study, again, self-administered “25I-NBOMe” as a blotter and 
admitted to the ED 6 hours after ingestion. Two seizures registered whilst being in the 
hospital, both treated with lorazepam. Serum specimens were obtained upon arrival 
and 4 hours post-arrival containing 25B-NBOMe at 1.2 ng mL-1 and 0.51 ng mL-1 
respectively. Again, 25I-NBOMe was not detected.63 
 
Several other case studies of NBOMe ingestion have been noted by Al-Imam64 who 
summarises 13 intoxication and fatality incidents between 2013 and 2015. The 11 
males and 2 females, largely from the USA, included in this study were aged between 
15 – 31 years old. Outcomes from ingestion included death, intoxication and potential 
suicide. In most of the cases of death (9 cases), 6 of these were due to 25I-NBOMe. 
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This led to the analysis of NBOMe’s becoming vital in the knowledge of thresholds and 
how to treat patients who had ingested this class of drugs. 
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1.2.5 NBOMe Analysis 
Analysis of NBOMe’s can be determined on the nature that they are presented in, 
which is often as blotters. Poklis et al.11 have reported a work on the analysis of 
blotters. The authors performed their analysis with direct analysis in real time mass 
spectrometry (DART-MS) followed by confirmation and quantification with high-
performance liquid chromatography triple quadrupole mass spectrometry (HPLC-MS-
MS). The advantages of the DART-MS technique are that it requires no solvent, 
extractions or solvent preparation. The authors reported that by holding the blotter 
paper into the direct gas stream, using forceps, a spectrum was yielded within 
seconds. They then combined this with the HPLC-MS-MS analysis to become the first 
to compare concentrations of the blotter to the advertised amount. They found the 
vendor’s blotter paper 25C-NBOMe had been correctly labelled with the drug, 
containing 102% of the labelled dose and 3.3% NBOMe derivative impurities. The 25I-
NBOMe blotter was determined to be correctly labelled with the drug, containing 108% 
of the labelled dose and 8.0% NBOMe derivative impurities. The 25B-NBOMe blotter 
was also determined to be correctly labelled with the drug, containing 300% of the 
labelled dose and 2.2% NBOMe derivative impurities.11 
 
Elbardisy et al.65 used high-performance liquid chromatography-photodiode array 
detection (HPLC-DAD) and high-performance liquid chromatography-amperometric 
detection (HPLC-AD). The photodiode array detection technique is used to determine 
the purity of an analyte during HPLC separation. It works similarly to a variable 
wavelength detector (VWD). However, this method has its advantage over 
conventional UV detectors due to its speed of scanning. Multiple scans occur during 
the array of diodes whereas VWD does one scan. This electrochemical approach was 
the first presentation of both photodiode array and amperometric detection for the 
simultaneous qualitative and quantitative analysis for NBOMe’s in a single run. The 
limit of detection (LOD) is low enough to target analytes within a seized blotter with 
both detection methods (HPLC-DAD 4.56 – 6.65 µg mL-1 and HPLC-AD 9.65 – 17.98 
µg mL-1). 
 
Duffau et al66 used a combination of high-performance thin-layer chromatography 
(HPTLC) and gas chromatography mass spectrometry (GC-MS). HPTLC is an 
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enhanced form of TLC, that increases the resolution to acquire more accurate 
quantitative measurements. 25C-NBOMe blotters were analysed from a seized batch, 
with the results varying from 701 to 1943.5 µg per blotter. The results here indicate 
the dangers associated with this derivative and its dosage, with intoxication and 
fatalities occurring with >1000 µg doses sublingually.67 They found that 8 of the 15 
blotters exceeded 1000 µg increasing the risk of acute intoxication because of its high 
potency. The LOD and LOQ associated with HPTLC is 7.1 and 21.63 µg respectively. 
 
Aside from HPLC based methods, blotter analysis can be performed via attenuated 
total reflection Fourier transform infrared (ATR-FTIR)68 and ultra-performance liquid 
chromatography (UPLC).69  
 
However, as mentioned on page 35, NBOMe ingestion requires biological analysis. 
Moreira et al.70 have detailed the variation in the value obtained by different 
methodologies due to the concentration found in biological matrices being generally 
very low (0.025 – 500 ng mL-1). Therefore, this requires a different extraction process 
and highly sensitive analytical techniques.  
 
Biological samples described for the identification and quantification of NBOMe 
compounds included whole blood,71, 72 plasma,71, 73 serum,74, 75 and urine.71, 76 For 
post-mortem, matrices included fluids,77, 78 tissues,79, 80 heart blood,69, 81 peripheral 
whole blood,77, 79 vitreous humor,13, 77 liver59, 77 and stomach contents ,77, 79 with a focus 
on urine77, 79 and serum31, 82 samples. The required volume of these biological samples 
for the analytical techniques employed for identification of new psychoactive 
substance (NPS) ranged from 0.5 to 1 mL.67, 71 
 
The two main extraction methods found by Moreira et al. included liquid-liquid 
extraction (LLE) and solid-phase extraction (SPE). 70 For assays using LLE, the linear 
range varied between 0.1 to 500 ng mL-1 whereas the SPE linear range varied 
between 25 pg mL-1 to 100 ng mL-1. The analytical techniques employed were gas 
chromatography with mass-spectrometry (GC-MS), high performance liquid 
chromatography coupled to positive ion-mode electrospray mass-spectrometry 
(ESI(+)-LC-MS/MS), and quantum time of flight (QTOF).  
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LLE methods are considered simpler but a time consuming process. However, due to 
its ease of handling, availability of materials, and low cost, it is still a widely used 
method. Rose et al.74 reported the identification of 25I-NBOMe using 1.0 mL of serum 
sample. This analyte was extracted with 2 mL hexane: ethyl acetate (1: 1, v/v). Thus, 
0.76 ng mL-1 of analyte was determined in the sample. Walterscheid et al.81 reported 
two cases of death following ingestion of the same analyte, which was confirmed by 
analysis of biological samples (heart blood and urine). In this assay, 0.5 mL of samples 
were analyzed using 2 mL of ethyl acetate and 0.2 mL of saturated alkaline sodium 
borate buffer (pH 12). The residue was suspended in 1 mL of 7 mM ammonia prepared 
with 10% acetonitrile buffer. Aliquots of the analyzed samples confirmed the presence 
of 25I-NBOMe (7.5 ng mL-1) in both cases. 
 
SPE methods are thought to be more advantageous than LLE, as lower volumes of 
solvent are required, extracts are cleaner and usually faster.83 To enhance the 
efficiency of SPE cartridges, a pre-treatment of the sample is desired. The most 
commonly used pre-treatment is denaturation of serum proteins with organic solvents 
(acetonitrile, acetone, ethanol and methanol), acids (10% w/v trichloroacetic, 6% w/v 
perchloric and 5% w/v metaphosphoric) or salts and metal ions (5% w/v copper sulfate 
and 6% w/v sodium tungstate). Generally, this pre-treatment is always applied before 
traditional extraction techniques (LLE and SPE) in search of a method that is fast, 
simple and inexpensive.84 Poklis et al.82 developed a method to determine two NBOMe 
in serum samples. The method was applied in samples of two patients who were 
admitted having used 25I-NBOMe. In this case, 2780 pg mL-1 of 25I-NBOMe was 
found in the samples. Hill et al.73 described seven cases of analytically confirmed 
toxicity due to the recreational use of the same analyte, and biological samples were 
analysed for all seven cases. Next, Poklis et al.77 reported a case detection of the 
same analyte in different biological samples. For post-mortem specimens, the results 
between the procedures were in good agreement and demonstrated a lack of matrix 
effects and ease of extraction of 25I-NBOMe from tissue matrices. Toxicology findings 
for fluids based upon blood or urine calibrators were as follows: 405 pg mL-1 in 
peripheral blood, 410 pg mL-1 in heart blood, 2.86 ng mL-1 in urine, and 99 pg mL-1 in 
vitreous humor. Poklis et al.76 also developed a method for the simultaneous 
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determination and quantification of nine NBOMe in urine samples. The method 
detected the presence of NBOMe derivatives in four specimens from emergency room 
patients. It was determined that one specimen contained only 25B-NBOMe at 1.7 ng 
mL-1, while another contained only 25I-NBOMe at 1.0 ng mL-1. A further specimen 
from another patient contained 2.3 ng mL-1 of 25I-NBOMe and <1.0 mg mL-1 of 2C-
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1.3 Hyperpolarisation Techniques 
The use of techniques to enhance nuclear spin polarization (P) to order unity (i.e. 
100%) results in corresponding gains in NMR sensitivity by 4–8 orders of 
magnitude.85 This process of significant polarization enhancement—well above that 
achieved at thermal equilibrium—is termed hyperpolarization. Hyperpolarization of 
solids, liquids, and gases86 has been demonstrated via a number of techniques 
including Brute Force Polarization (BFP),87 Spin Exchange Optical Pumping 
(SEOP),88 Dynamic Nuclear Polarization (DNP),89 Chemically-Induced Dynamic 
Nuclear Polarization (CIDNP)90 photo-CIDNP,91 Parahydrogen Induced Polarization 
(PHIP),92 and Signal Amplification By Reversible Exchange (SABRE).93  
 
1.3.1 SABRE Hyperpolarisation 
Signal amplification by reversible exchange (SABRE) is a non-hydrogenative 
polarisation technique that enhances the sensitivity of an NMR experiment by 
increasing the signal intensity. Although NMR, and by extension, MRI, are thought 
to be intrinsically insensitive techniques, polarisation techniques such as SABRE 
can vastly overcome this. Insensitivity arises due to the distribution of nuclear spins 
being almost equal and this means that only a very small fraction of spins actively 
contribute in terms of producing a signal.  
 
The source of polarisation in SABRE is parahydrogen, a spin isomer of dihydrogen. 
Parahydrogen is a nuclear singlet (total spin of zero), and is, therefore, NMR silent. 
However, by breaking the symmetry of parahydrogen, the polarised state can be 
accessed. In the right conditions, this polarisation can be transferred to other 
molecules. 
 
Transfer of polarisation in SABRE occurs through the J-coupling from a para-
hydrogen-derived hydride ligand to spin-½ nuclei of those associated with the 
analyte molecule (Figure 6).94 A metal “catalyst” is used to facilitate polarisation 
transfer. These catalysts, which are typically iridium centred, catalyse the transfer 
of polarisation and not chemical change, as unlike PHIP, SABRE does not lead to 
the chemical modification of the substrate. As polarisation transfer occurs through 
 
 
42 | P a g e  
 
the J-coupling, coupling is maximised for analyte molecules trans to parahydrogen-
derived hydrides, whereas polarisation transfer to molecules that are cis is 
negligible.  
 
The analyte molecule is required to have a ligation point for which to ligate to the 
metal catalysts. Nitrogen heterocyclic molecules have been extensively explored in 
the literature.95-100 24 - 26 all possess a pyridyl motif and so, theoretically, could be 
potentially SABRE active. Pyridine is the most studied N-heterocycle for SABRE. 
Using this technique, it may be possible to successfully image the binding of NBOMe 
derivatives, such as 24 - 26 to 5-HT receptors. This may offer an alternative 
technique to PET imaging. 
 
SABRE was first reported in 2009 by Duckett and co-workers when it was 
demonstrated that PHIP could occur without the incorporation of parahydrogen into 
the analyte.101 By using an iridium-based catalyst, spin polarisation was transferred 
at low magnetic field ligands (typically 0.5 to 150 G (0.5 to 150 x10-4 T)) to 15N-
labelled pyridine. 15N-labelled pyridine, therefore, became the first compound to 
demonstrate that SABRE did not chemically change the analyte and that a catalyst 
was required to facilitate transfer of spin magnetisation. This initial observation was 
sufficient to demonstrate the applicability of this technique to both NMR and MRI, 
and it led to the phrase SABRE being coined to describe this technique.102 In a 
second publication, a range of N-heterocyclic ligands, such as nicotine and 3-
fluoropyridine, were polarised by SABRE in CD3OD. The polarisation transfer was 
evident by inspection of the resulting polarised 1H, 13C, 19F and 31P NMR spectra 
that were recorded relative to their normal Boltzmann distribution. In terms of signal 
gain, the enhancement of the 1H spins of pyridine increased by 550-fold 
(Polarization (P) = 0.4%) following polarisation transfer at 2 × 10-2 T. In this instance, 
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Figure 6 - Catalytic cycle of parahydrogen (red) binding to an iridium based catalyst 
via oxidative addition (A) followed by reductive elimination of orthohydrogen (blue) 
from the complex (B) and lastly pyridine substrate binding to the iridium complex 
(C), which can then dissociate after polarisation transfer so the process can start 
again. 
 
Richardson et al.103 have since shown, in 2018, that SABRE has progressed and an 
enhancement for pyridine increased greatly. The polarisation performed via high 
field NMR (9.4 T, 400 MHz) yielded ortho-proton enhancement values of 1610-fold 
and low field NMR (1 T, 43 MHz) yielded an ortho enhancement of 17100-fold using 
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1.4 Positron Emission Tomography (PET) 
Molecular imaging involves the in vivo examination of molecular and cellular 
processes through the application of a number of imaging techniques, including 
positron emission tomography (PET),104 single-photon emission computed 
tomography (SPECT),105 magnetic resonance imaging (MRI)106 and optical 
imaging.107 
 
Of all the tomographic molecular imaging modalities, PET imaging offers more 
translational possibilities than any other modality due to its combination of sensitivity 
and quantitative accuracy. PET is a non-invasive imaging modality that provides 
physiological information through the injection of radioactive compounds 
(radiotracers), detection of radiation, and reconstruction of the distribution of the 
radiotracer.104. The radioisotopes frequently used include 18F, 11C, 15O, 13N, 82Rb, 
64Cu and 68Ga, with 18F and 11C being the most popular due to their longer half life 
time (109.77 and 20.33 min respectively) and can also be used in drug compounds 
as they have no pharmacological effect.108 
 
The evolution of this technique has become a standard component of diagnosis and 
staging in oncology, along with specific neurological and cardiovascular indications. 
It is known that the NBOMe series has a high binding affinity with the serotonin 
receptors (5-HT) so by altering the structure of the molecule it can be used as a PET 
agent for studies on neuropsychiatric disorders.109 To further enhance binding, 
classical receptor binding assays have demonstrated that 5-HT2A receptors exists 
in two affinity states, agonistic and antagonistic.110 NBOMe related compounds 
(Figure 7), Cimbi-5 (20) and Cimbi-36 (21), have agonistic binding properties to the 
5-HT2A receptor.111 [18F] Altanserin112 (22) and [11C]MDL 100907113 (23), have been 
found not to be displaced by elevated levels of endogenous serotonin (5-HT) as they 
are antagonists,114 so it would not be suitable for PET imaging studies. By changing 
the substituted benzaldehyde to a substituted nicotinaldehyde (Figure 8), a potential 
new range of compounds (NPyr 24, NPF 25 and NPOMe 26) can be approached 
with a different analytical technique (hyperpolarisation). 
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Figure 7 – Previous radio ligands involved with 5-HT2A studies 
 
 
Figure 8 – Proposed structures to replace PET imaging compounds (X=F, Cl, Br, I, 
Me, Et, NO2) 
 
5-Hydroxytryptamine (serotonin, 5-HT) receptors are scattered throughout the body 
as they mediate a wide range of physiological processes. These receptors are found 
in the central and peripheral nervous system (CNS/PNS), as well as in a number of 
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non-neuronal tissues in the gut, cardiovascular system and blood. Dysfunction of 
these has been implicated in cardiovascular and digestive disorders as well as 
numerous psychiatric disorders.115 Pharmacological manipulation of the 5-HT 
system is believed to have therapeutic potential, and is therefore the subject of 
intense research.116 The 5-HT receptor branches off into seven different subtypes, 
with evidence showing there are at least 14 mammalian subtypes in existence.117 
All the 5-HT receptors are G protein-coupled receptors (GPCRs), with the exception 
of the 5-HT3 receptor (ligand-gated ion channel).117,118 The 5-HT2 family has three 
known subtypes: 2A, 2B and 2C. The transmembrane domains of the 5-HT2A and 5-
HT2C receptors share an 80% sequence identity and possess similar 
pharmacological profiles.119 
 
NBOMe’s are known to be potent partial agonists for the 5-HT2A receptor, which is 
comprised of 471 amino acids and is widely distributed in peripheral and central 
tissues.115 This receptor plays a physiological role in working memory,120 the 
regulation of cognitive states and associative learning.121 Peripheral 5-HT2a 
receptors mediate diverse processes such as vasoconstriction and platelet 
aggregation.122 Various other responses have been observed and these are 
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Figure 9 - Graphical representation of the known 5-HT2A signalling pathways. The 5-HT2A receptor couples to various downstream effectors 
enabling diverse cellular responses following receptor activation. Some of the mediating proteins (MP) are omitted for clarity. Mediating proteins 
(MP1) in the Gα12/13-hoAMKK4. p38 pathway most probably are PKN, MEKK, MKK3/6 and Shc, Grb2 and SOS are the proteins mediating (MP2) 
the Ras-Raf-MEK1,2-ERK1,2 pathway. Receptor regulatory pathways (e.g. phosphorylation; internalization; desensitization) following agonist 
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By incorporating radionuclei (e.g. [11C]) within the NBOMe structure, these 
molecules have been employed as radiotracers to visualise the release patterns of 
serotonin receptors using PET MRI. This also includes diseases that arise from 
these faulty receptors, including depression, anxiety, obsessive-compulsive 
disorders (OCD) and schizophrenia. The radiosynthesis and the use of these 
molecules have been investigated.43 
 
PET studies of 5-HT2 receptors have shown that agonist PET tracers are more 
displaceable by elevated levels of endogenous dopamine compared to antagonist 
tracers.124, 125 PET imaging allows for the quantification of neuroreceptors, and with 
the appropriate radioligand, neurotransmitter release can be detected as receptor 
binding will be inversely correlated to extracellular levels of neurotransmitters such 
as has been shown for the dopamine system.126 Therefore, PET imaging has the 
potential to measure serotonin levels in the human brain safely. A radioligand has 
not yet been fully developed that is sensitive enough to detect the change in 
serotonin levels. Ettrup et al. has since developed and validated a series of 
NBOMe’s as agonist PET radioligands for the selective mapping and quantification 
of 5-HT2A receptors in vivo,111, 43 with [11C]Cimbi-36 (Scheme 5, 21) having the 
strongest PET tracer properties when scanned in a pig brain. When looking at the 
other results such as whole body distribution and head twitch response (HTR), it 
was found that the lungs had the highest uptake in rats, whereas in pigs it was the 
excretory organs (bladder, gall bladder and kidneys) (Figure 10).127 The in vivo 
pharmacological effects showed that the HTR in mice was most comparable to 
saline, with a prominent HTR with Cimbi-36 at a higher dose of 0.5 mg/kg. This 
suggests, for humans, doses between 300 – 600 µg will yield hallucinogenic effects. 
However, the doses generally given in PET scanning are in the low µg range (ca. 1 




49 | P a g e  
 
 
Figure 10 - Ettrup et al. imaging data of the sagittal whole body PET images of 
[11C]Cimbi-36 distribution in a pig. Images are averaged over the indicated time 
interval and are overlaid on to the corresponding section in the CT image. Images 
are scaled to standardised uptake values (SUVs) as given by the colour bar. PET 
images are threshold so that voxels with SUV values lower than 0.2 % of the 
maximal volumetric pixel (voxel) value are not shown.127 
 
Ettrup and co-workers then looked at how Cimbi-36 binds to the human brain. 
Twenty-nine healthy males participated in this study with the results being that 
Cimbi-36 successfully labelled the 5-HT2A receptor. However, as these compounds 
are comprised of labelled [11C] (Scheme 5), they only have a half-life of 20 minutes. 
Therefore implementing these PET tracers will have to be done in a time efficient 
manner to ensure that appropriate images can still be acquired. 
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1.5 Aims and Objectives 
Since the introduction of misuse of drugs act, illicit drug suppliers and clandestine 
labs have been looking at ways to avoid detection and alter structures of controlled 
substances. An example of this would be to include fluorine into the molecule, as 
research has indicated that this enhances biological activity and increased chemical 
and metabolic stability.128 This has also lead to the suppliers mixing drugs, so the 
“research chemicals” being sold by these vendors are not necessarily what it says 
they are, with the dosing also being potentially wrong. However, NBOMe studies 
have looked at the positive aspects of this illicit drug by altering them to radio 
labelled compounds to be used in PET imaging. The aim of this project, outlined in 
Scheme 6, is to synthesise NBOMe compounds as reference standards for street 
sample analysis including GC-MS validation and presumptive testing of 
impregnated blotters. This is complemented by the synthesis of 21 novel 
compounds, which could potentially replace PET imaging agents, with polarisable 
pyridyl tethers such that they could be hyperpolarised via SABRE.  
 
Scheme 6 – Objectives for the research presented; X = F, Cl, Br, I, Me, Et, NO2; 
25X-NPyr (24) – R1 = R2 = H; 25X-NPF (25) – R1 = F, R2 = H; 25X-NPOMe (26) – 
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2 Chapter 2 - Experimental 
2.1 Apparatus Used 
All chemicals were obtained from Sigma Aldrich (Gillingham, UK), Fluorochem 
(Hadfield, UK) or Tokyo Chemical Industry (Oxford, UK) and used without further 
purification. 1H- and 13C-NMR spectra were acquired on a JEOL ECS 400 (JEOL, 
Hertfordshire, UK) NMR spectrometer operating at a proton resonance frequency of 
400 MHz and carbon resonance frequency of 101 MHz. 1H-NMR analysis performed 
on a Pulsar (Oxford Instruments, Abingdon, UK) NMR spectrometer, operating at a 
resonance frequency of 60 MHz, was acquired in 1 scan using a filter file of 2000 
Hz and a relaxation delay of 0.01 seconds. Infrared spectra were obtained in the 
range 4000 – 400 cm−1 using a ThermoScientific Nicolet iS10ATR-FTIR instrument 
(ThermoScientific, Rochester, USA). GC-MS spectra were recorded on an Agilent 
7890B gas chromatograph with split-splitless injection (sample volume: 0.5 µL), split 
ratio of 50:1 and a HP-5MS column (30 m × 0.25 mm, 0.25 µm film thickness). 
Helium (He) was used as the carrier gas at a flow rate of 1.2 mL min-1. The GC was 
coupled to an Agilent 5977 MSD (EI, 70 eV, TIC mode scanning m/z 50 – 500) and 
injector port was set at 265 °C, the transfer line at 300 °C. The following temperature 
program was used: 50°C, ramped by a rate of 30°C min-1 to 320°C and held for 3 
min. Thin-Layer Chromatography (TLC) was carried out on aluminium-backed SiO2 
plates (Merck, Darmstadt, Germany) and spots were visualised using ultra-violet 
light (254 nm).  
 
2.2 Presumptive Test Reagents 
Presumptive tests reagents were prepared according to the United Nations 
recommended guidelines.129 The following standard presumptive tests applied in 
this study: (i) Marquis; (ii) Liebermann. Sample solutions were prepared at 10 mg 
mL-1 by dissolving the reference standards in distilled water. Negative control 
samples (distilled water) were used in all tests in order to indicate clearly when a 
positive result occurred.  
 
Marquis Test: 1% formaldehyde (37% aqueous solution) in concentrated sulfuric 
acid (10 mL). 5 drops of test sample in distilled water (10 mg mL-1) was placed into 
a dimple well of a white spotting tile and 5 drops of the test reagent added. Any 
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immediate colour change or other noticeable effect occurring was noted and 
observations were made again after a 5 minute period. 
 
Liebermann test: Potassium nitrite (2 g) in concentrated sulfuric acid (20 mL). 5 
drops of test sample in distilled water (10 mg mL-1) was placed into a dimple well of 
a white spotting tile and 5 drops of the test reagent added. Any immediate colour 
change or other noticeable effect occurring was noted and observations were made 
again after a 30 minute period.  
 
2.3 Developed GC-MS method for NBOMe separation 
A method was created (stated in apparatus used) for the separation of NBOMe 
analogues by GC-MS. A SIM detection mode was used for the increased sensitivity 
when identifying each NBOMe, with the SIM ions being m/z = 91.1, 121.1 and 151.1.  
 
2.4 Reference standard preparation for GC-MS 
All compounds were prepared as 1 mg mL-1 solutions for initial GC-MS screening. 
3-4 mg of each reference material dissolved in MeOH to the matching volume (3 – 
4 mL) in 5 mL volumetric flasks. 
 
2.5 NBOMe calibration standards for GC-MS 
5 mg of each NBOMe was weighed and diluted to 5 mL with MeOH to give a 1 mg 
mL-1 solution. This solution was then further diluted with MeOH (10 mL) to give a 
100 µg mL-1 solution. This was diluted further with MeOH (0.3 – 0.6 mL) and 0.75 
mL eicosane (25 µg mL-1 in MeOH) to give calibration standards containing 10 µg 
mL-1, 15 µg mL-1, 20 µg mL-1, 25 µg mL-1 and 30 µg mL-1. 
 
2.6 Blotter preparation 
Pre-perforated blotting paper (1/4” x 1/4”) (Amazon, Zane Kesey, UK) were 
prepared and analysed by the following techniques; 0.2 mL of 300 ug mL-1 25B-
NBOMe, 500 ug mL-1, 25C-NBOMe and 800 ug mL-1 25I-NBOMe in MeOH was 
dripped evenly onto a 3 x 3 (3/4” x 3/4") block of papers (plain and patterned) and 
left to dry. For the extraction, 1 mL MeOH was added to 1 blotter per vial and ultra-
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sonicated for 15 mins, the solution was pipetted into a separate vial and the blotter 
was re-extracted with 1 mL MeOH. This process was repeated 3 times and the 
MeOH collections concentrated in vacuo. Appropriate dilutions was applied so the 
concentrations are in the calibration range with eicosane (12.5 ug mL-1) being the 
internal standard. 
 
2.7 Sample Preparation for SABRE experiments 
5 mM of an iridium based catalyst [Ir(COD)(IMes)Cl] (COD = cyclooctadiene, IMes 
= 1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene)130 (85) was used with 4 mol eq. 
of the selected substrate (catalyst synthesised by a PhD colleague, Thomas 
Robertson, Dr Ryan Mewis research group). The solvent used was methanol-d4 and 
the total volume used was 0.6 mL in each sample. NMR samples were prepared in 
5 mm diameter NMR tubes fitted with Youngs caps, samples were degassed on a 
high-vacuum line via three ‘cool’-pump-thaw cycles (using a acetone/CO2 slush 
bath). Parahydrogen, at a pressure of 3.0 atmospheres, was then admitted to the 
NMR tube. Parahydrogen was produced by cooling hydrogen gas to 77 K over 
charcoal.  
 
Preparation for SABRE experiments followed A. M. Olaru et al.131. NMR samples 
were prepared containing 5 mM catalyst precursor in 0.6 mL of methanol-d4. Arrays 
of NMR measurements were collected using either 4 equivalents of substrate to 5 
mM of iridium in 0.6 mL MeOD (leading to samples containing 1- and 17-fold 
excesses of ligand relative to iridium, respectively). After adding p-H2 at 3 bar 
pressure, 1H NMR spectra were recorded using π/2 excitation pulses immediately 
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2.8 Compound data 
Synthesis of 2-(4-bromo-2,5-dimethoxy-phenyl)ethanamine (28) 
 
2,5-Dimethoxyphenethylamine (2C-H) (4.96 g, 27.7 mmol) was added to glacial 
acetic acid (40 mL). To this solution was added bromine (4.4 g, 27.7 mmol) in glacial 
acetic acid (8 mL) slowly. The solution was then left to stir at RT for 5 min. A yellow 
solid spontaneously formed exothermically and was left to cool down to room 
temperature before filtering. The filtrate was dissolved in aqueous NaOH (25% w/v), 
extracted with DCM (3 x 100 mL) and dried in vacuo to obtain a white oil. The oil 
was dissolved in a mixture of water (50 mL), acetic acid (6.7 mL), and conc. HCl (12 
M, 20 mL) to obtain the hydrochloride salt. The precipitate was collected via filtration. 
This was then washed sequentially with water (60 mL), Et2O (150 mL) and acetone 
(60 mL) to obtain a pure white powder (3.51 g, 49 %); Mp. 236-238°C; 1H NMR (400 
MHz, CD3OD) δ 7.18 (s, 1 H), 6.97 (s, 1 H), 3.84 (s, 3 H), 3.82 (s, 3 H), 3.14 (t, 
J=7.22 Hz, 2 H), 2.95 (t, J=7.22 Hz, 2 H); 13C NMR (101 MHz, CD3OD) δ 153.5, 
151.8, 126.4, 117.2, 116.4, 111.4, 57.5, 56.7, 40.7, 29.8. GC-MS 6.856 min, 
m/z=230. Data corresponds to the spectroscopic assignments reported by 
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Synthesis of 4-chloro-2,5-dimethoxy-benzaldehyde (29)  
 
The approach of Wright et al133 was used with an argon-flushed system to suspend 
hexamethylenetetramine (1.40 g, 10 mmol) in 1-chloro-2,5-dimethoxybenzene (1.26 
g, 7.32 mmol) to which was added TFA (25 mL) dropwise with stirring until the 
solution was yellow. This was heated to reflux for 15 h with the brown solution 
poured onto ice (25 g) and NaHCO3 added in slowly until a yellow solid formed and 
the solution is basic. The solid was filtered and washed with water then dissolved in 
Et2O. The organic solution washed with water, brine, dried with MgSO4 and dried in 
vacuo to obtain a crude yellow/brown product. The aldehyde was recrystallized with 
high b.p petroleum ether (80-100ºC) and the yellow powder filtered yielding (0.80 g, 
55 %); Mp. 158-161 °C; 1H NMR (400 MHz, CDCl3) δ 10.39 (s, 1 H), 7.38 (s, 1 H), 
7.07 (s, 1 H), 3.90 (s, 6 H); GC-MS 6.061 min, m/z = 200 (M+). Data corresponds to 
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Synthesis of 1-chloro-2,5-dimethoxy-4-[(E)-2-nitrovinyl]benzene (30) 
 
29 (8.80 g, 36.2 mmol), nitromethane (3.31 g, 54.3 mmol) and ammonium acetate 
(6.98 g, 90.5 mmol) were added to acetic acid (60 mL). The solution was then stirred 
to reflux for 4 hr. After cooling, water was added until a yellow/orange solid formed, 
which was then left to stir for a further 10 min in an ice bath. This was filtered and 
washed with water as a yellow/orange solid. The nitrostyrene was recrystallized with 
IPA and filtered to yield a yellow powder (2.99 g, 34 %); Mp. 158-160°C; 1H NMR 
(400 MHz, CDCl3) δ 8.08 (d, J=13.74 Hz, 1 H), 7.87 (d, J=13.74 Hz, 1 H), 7.03 (s, 1 
H), 6.98 (s, 1 H), 3.91 (s, 3 H), 3.92 (s, 3 H;. 13C NMR (101 MHz, CDCl3) δ 153.725, 
149.272, 138.479, 134.494, 127.610, 117.856, 114.690, 113.956, 56.739, 56.615, 
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Synthesis of 2-(4-chloro-2,5-dimethoxy-phenyl)ethanamine (31) 
 
In an argon-flushed system, lithium aluminium hydride (0.5 g, 13 mmol) was 
suspended in anhydrous THF (50 mL) and the solution was stirred thoroughly. 30 
(0.61 g, 2.5 mmol) dissolved in THF (10 mL) was added in slowly and stirred for 3 h 
at RT prior to heating to reflux for 15 min. The remaining LAH was decomposed by 
water (5 mL) followed by aqueous NaOH (15%, 5 mL) in an ice bath to precipitate 
out the basic insoluble components. The solution was then filtered and the filtrate 
washed with THF (3 x 40 mL). The organic solution was concentrated in vacuo and 
2M HCl (20 mL) was added. This solution was washed with DCM (3 x 20 mL) and 
the aqueous layer then neutralised with aqueous NaOH. This was extracted with 
DCM (5 x 20 mL), dried with MgSO4 and concentrated in vacuo. The amber oil was 
dissolved with IPA (10 mL), neutralised with conc. HCl (12 M) and upon addition of 
anhydrous ether crystals formed. The salt was recrystallized with IPA and filtered 
yielding a white powder (0.27 g, 50%); Mp. 240-242°C; 1H NMR (400 MHz, CD3OD) 
δ 7.04 (s, 1 H), 6.98 (s, 1 H), 3.82 (s, 3 H), 3.84 (s, 3 H), 3.14 (t, J=7.33 Hz, 2 H), 
2.95 (t, J=7.33 Hz, 2 H). 13C NMR (101 MHz, CD3OD) δ 153.22, 150.70, 125.60, 
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Synthesis of 2,5-dimethoxy-4-methyl-benzaldehyde (32) 
 
Phosphorus(V)oxychloride (20 mL, 0.8 mol) and N-methylformanilide (22.5 mL, 0.15 
mol) was stirred at room temperature for 1 h until the solution went orange indicating 
the formation of the Vilsmeier complex. 2,5-dimethoxytoluene (7.15 mL, 0.05 mol) 
was added and heated to 70°C for 2 h. The heat source was removed and allowed 
to cool to room temperature. The flask was reheated, poured into ice water (1 L) 
and stirred for 10 mins. The solution was filtered and the crude aldehyde collected 
as a red solid. This was suspended in boiling petroleum ether (50 mL) and decanted; 
this process was repeated twice. The solution was left to crystallize and filtered to 
obtain 2,5-dimethoxy-4-methylbenzaldehyde as a white powder (8.86 g, 97%); 1H 
NMR (400 MHz, CD2Cl2) δ 10.4 (s, 1 H), 7.2 (s, 1 H), 6.8 (s, 1 H), 3.9 (s, 3 H), 3.8 
(s, 3 H), 2.3 (s, 3 H). Data corresponds to the spectroscopic assignments reported 
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Synthesis of 2,5-dimethoxy-1-methyl-4-[(E)-2-nitrovinyl]benzene (33) 
 
32 (8.86 g, 50 mmol), nitromethane (75 mmol) and ammonium acetate (9.64 g, 125 
mmol) were added to acetic acid (90 mL). The solution was then heated to reflux, 
with stirring, for 4 hr. After cooling, water was added until a yellow/orange solid 
formed, which was then left to stir for a further 10 min in an ice bath. This was filtered 
and washed with water (20 mL) to afford a yellow/orange solid. The nitrostyrene was 
recrystallized with IPA and filtered yielding a yellow powder (7.38 g, 66%); 1H NMR 
(400 MHz, CDCl3) δ 8.1 (d, J=13.74 Hz, 1 H), 7.9 (d, J=13.28 Hz, 1 H), 6.8 (s, 1 H), 
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Synthesis of 2-(2,5-dimethoxy-4-methyl-phenyl)ethanamine (34) 
 
In an argon-flushed system, lithium aluminium hydride (6.73 g, 0.18 mol) was 
suspended in anhydrous THF (200 mL) and the solution was stirred thoroughly. 33 
(7.38 g, 0.03 mmol) was dissolved in THF (40 mL) and was added in slowly, this 
was stirred for 3 h at RT then refluxed for 15 min. The remaining LAH was 
decomposed by water followed by NaOH (15%, 10 mL) to precipitate out the basic 
insolubilities, this was then filtered and the filtrate washed with THF (3 x 40 mL). The 
organic solution was concentrated in vacuo and HCl (2 M, 20 mL) was added. This 
was washed with DCM (3 x 20 mL) and the aqueous layer then neutralised with 
aqueous NaOH. This was extracted with DCM (5 x 20 mL), dried with MgSO4 and 
concentrated in vacuo. The amber oil was dissolved with IPA (10 mL), neutralised 
with conc. HCl (12 M) and upon addition of anhydrous ether (10 mL) crystals formed. 
The salt was recrystallized with IPA and filtered yielding a white powder (0.92 g, 
14%); 1H NMR (400 MHz, CD3OD) δ 6.7 - 6.7 (m, 1 H), 6.7 (s, 1 H), 3.8 (dd, J=3.89, 
1.60 Hz, 6 H), 2.8 (d, J=6.87 Hz, 2 H), 2.7 (d, J=6.87 Hz, 2 H), 2.2 (s, 3 H); 13C NMR 
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Synthesis of 2,5-dimethoxyacetophenone (35) 
 
1,4-dimethoxybenzene (24.7g, 0.18 mol) was dissolved in DCM (50 mL) and added 
slowly to a stirred solution of acetyl chloride (22 g, 0.23 mol), aluminium chloride 
(30.6 g, 0.23 mol) and DCM (70 mL) with external cooling. This was stirred for 1 h 
at RT then poured into H2O (200 mL) and extracted with DCM (4 x 50 mL). The 
organic layer washed with 5% NaOH (3 x 50 mL) and concentrated in vacuo to afford 
a red oil, 2,5-dimethoxyacetophenone (26.86 g, 83%); 1H NMR (400 MHz, CDCl3) δ 
7.3 (d, J=3.21 Hz, 1 H), 7.0 (dd, J=8.93, 3.21 Hz, 1 H), 6.9 (d, J=8.93 Hz, 1 H), 3.9 
(s, 3 H), 3.8 (s, 3 H), 2.6 (s, 3 H). Data corresponds to the spectroscopic 









After acidification of the spent aqueous phase (HCl, 2 M) and extraction with DCM 
(3 x 40 mL), the organic solution washed with saturated NaHCO3 and concentrated 
in vacuo. 2-hydroxy-5-methoxyacetophenone was produced as yellow crystals and 
recrystallized with MeOH, dried and filtered yielding (2.68 g, 9%); 1H NMR (400 
MHz, CDCl3) δ 11.9 (s, 1 H) , 7.2 (d, J=3.21 Hz, 1 H), 7.1 (dd, J=8.93 3.21 Hz, 1 H), 
6.9 (d, J=8.93 Hz, 1 H), 3.8 (s, 3 H), 2.6 (s, 3 H). Data corresponds to the 
spectroscopic assignments reported by Saito et al.137 Iodomethane (1.5 mol eq.) 
was added dropwise to a solution of 36 (1 mol eq.), KOH (10 mol eq.) and DMSO 
(50 mL). The solution was stirred for 1 h at 40°C. The mixture was then neutralised 
with sat. NH4Cl and extracted with DCM (4 x 25 mL). The organic phase was washed 
with water (8 x 40 mL), dried with Na2SO4 and concentrated in vacuo. No further 
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Synthesis of 2-ethyl-1,4-dimethoxybenzene (37) 
 
With a Dean-Stark set up, 35 (28.86 g, 0.15 mol), KOH (18.3 g, 0.33 mol), triethylene 
glycol (125 mL) and 40% hydrazine hydrate (32 mL) was heated to 150°C until no 
more water was produced, whereupon  the solution was maintained at reflux for a 
further 3 h. After cooling, the reaction mixture and distillate was poured into water 
(1 L) and extracted with DCM (4 x 50 mL), dried with NaSO4 and concentrated in 
vacuo to afford a deep red oil. This was purified via column chromatography (EtOAc-
hexane; 1:9 v/v) and concentrated in vacuo to obtain 2-ethyl-1,4-dimethoxybenzene 
as a deep red oil (3.0007 g, 12%); 1H NMR (400 MHz, CDCl3) δ ppm 6.8 (d, J=9.16 
Hz, 2 H), 6.7 (dd, J=3.20 Hz, 1 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 2.6 (q, J=7.33 Hz, 2 H), 
1.1 - 1.3 (m, 3 H). Data corresponds to the spectroscopic assignments reported by 









Acidification of the previous aqueous phase with conc. HCl (2 M) was extracted with 
DCM (4 x 50 mL) and concentrated in vacuo to a deep red residue. This was distilled 
at 115 – 120 °C at 6 mm/Hg to obtain a light red oil that was 2-ethyl-4-
methoxyphenol (19.38 g, 87%); 1H NMR (400 MHz, CDCl3) δ 6.7 (dd, J=4.81, 2.98 
Hz, 1 H), 6.7 (dd, J=4.58, 2.75 Hz, 1 H), 6.6 (dd, J=5.95, 2.70 Hz, 1 H), 5.2 (br. s, 1 
H), 3.8 (s, 3 H), 2.6 (dq, J=12.80, 9.60 Hz, 2 H), 1.2 (dt, J=23.81, 7.33 Hz, 3 H). 
Data corresponds to the spectroscopic assignments reported by Wang et al.139 
Iodomethane (1.5 mol eq.) was added dropwise to a solution of 38 (1 mol eq.), KOH 
(10 mol eq.) and DMSO (50 mL). The solution was stirred for 1 h at 40°C. The 
mixture was then neutralised with sat. NH4Cl and extracted with DCM (4 x 25 mL). 
The organic phase was washed with water (8 x 40 mL), dried with Na2SO4 and 
concentrated in vacuo. No further purification was required for 37 and was 






65 | P a g e  
 
Synthesis of 4-ethyl-2,5-dimethoxy-benzaldehyde (39) 
 
37 (20.57 g, 0.124 mmol) and tin (IV) chloride (64.6 g, 0.248 mol) were dissolved in 
anhydrous DCM (80 mL) and cooled to 0 °C. Dichloromethyl methyl ether (15.68 g, 
0.136 mol) was dropped in slowly overtime and left to stir until it reached room 
temperature. The solution was quenched in ice (100 g) with conc. HCl (12 M, 40 
mL) and stirred o/n. The organic layer was separated and washed (2 x 40 mL) with 
10% HCl, 1 M NaOH, water and brine and concentrated in vacuo to a white powder 
(20.2 g, 83%) with no further purification; 1H NMR (400 MHz, CDCl3) δ ppm 10.4 (s, 
1 H), 7.3 (s, 1 H), 6.8 (s, 1 H), 3.9 (s, 3 H), 3.8 (s, 3 H), 2.7 (q, J=7.63 Hz, 2 H), 1.2 
(t, J=7.56 Hz, 3 H). Data corresponds to the spectroscopic assignments reported by 
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Synthesis of 1-ethyl-2,5-dimethoxy-4-[(E)-2-nitrovinyl]benzene (40) 
 
39 (20.2 g, 0.104 mol), nitromethane (63.8 g, 1.04 mol) and ammonium acetate 
(2.67 g, 0.035 mol) was heated to reflux, with stirring, for 4 hr. After cooling, this was 
concentrated in vacuo to afford the crude nitrostyrene. After recrystallisation with 
IPA, this was filtered yielding a yellow powder (7 g, 29%); 1H NMR (400 MHz, CDCl3) 
δ 8.1 (d, J=13.74 Hz, 1 H), 7.9 (d, J=13.74 Hz, 1 H), 6.9 (s, 1 H), 6.8 (s, 1 H), 3.9 (s, 
3 H), 3.8 (s, 3 H), 2.7 (q, J=7.33 Hz, 2 H), 1.2 (t, J=7.33 Hz, 3 H); 13C NMR (101 
MHz, CDCl3) δ ppm 154.2, 151.4, 139.6, 137.4, 135.7, 116.4, 112.7, 112.6, 55.9, 
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Synthesis of 2-(4-ethyl-2,5-dimethoxy-phenyl)ethanamine (41) 
 
In an argon-flushed system, lithium aluminium hydride (5.8 g, 0.15 mol) was 
suspended in anhydrous THF (200 mL) and the solution was stirred thoroughly. 40 
(7 g, 0.03 mol) was dissolved in THF (40 mL) was added in slowly, and this was 
stirred for 3 h at RT then refluxed for 15 min. The remaining LAH was decomposed 
by water followed by NaOH (15 %, 10 mL) to precipitate out the basic insolubilities, 
this was then filtered and the filtrate being washed with THF (3 x 40 mL). The organic 
solution was concentrated in vacuo and HCl (2 M, 20 mL) was added. This was 
washed with DCM (3 x 20 mL) and the aq. layer then neutralised with aqueous 
NaOH. This was extracted with DCM (5 x 20 mL), dried with MgSO4 and 
concentrated in vacuo. The amber oil was dissolved with IPA (10 mL), neutralised 
with conc. HCl (12 M) and upon addition of anhydrous ether crystals formed. The 
amber oil was dissolved with IPA (10 mL), neutralised with conc. HCl (12 M) and 
upon addition of anhydrous ether crystals formed. The salt was filtered and washed 
with ether yielding a white powder (3.21 g, 50 %); 1H NMR (400 MHz, CD3OD) δ 6.8 
(s, 1 H), 6.8 (s, 1 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.1 - 3.2 (m, 2 H), 2.9 - 3.0 (m, 2 H), 
2.6 (q, J=7.33 Hz, 2 H), 1.2 (t, J=7.56 Hz, 3 H); 13C NMR (101 MHz, CD3OD) δ 
153.0, 152.9, 134.0, 123.6, 114.7, 113.6, 56.6, 56.4, 41.2, 30.0, 24.6, 15.1; GC-MS 
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Synthesis of 4-fluoro-2,5-dimethoxy-benzaldehyde (42) 
 
1-Fluoro-2,5-dimethoxybenzene (4.07 g, 26 mmol) and tin (IV) chloride (13.4 g, 51 
mmol) were dissolved in anhydrous DCM (25 mL) and cooled to 0 °C. 
Dichloromethyl methyl ether (2.64 g, 23 mmol) was dropped in slowly overtime and 
left to stir until it reached room temperature. The solution was quenched in ice (50 
g) with conc. HCl (12 M, 10 mL) and stirred o/n. The organic layer was separated 
and washed (2 x 10 mL) with 10% HCl, 1 M NaOH, water and brine and 
concentrated in vacuo to a white powder. This was recrystallized with EtOH and 
filtered yielding a white powder (1.39 g, 30 %); Mp. 99 °C; 1H NMR (400 MHz, CDCl3) 
δ 10.37 (s, 1 H), 7.45 (d, J=9.62 Hz, 1 H), 6.79 (d, J=12.36 Hz, 1 H), 3.89 (d, J=0.92 
Hz, 6 H); GC-MS 5.368 min, m/z 184. Data corresponds to the spectroscopic 




69 | P a g e  
 
Synthesis of 1-fluoro-2,5-dimethoxy-4-[(E)-2-nitrovinyl]benzene (43) 
 
42 (3.57 g, 15.7 mmol), nitromethane (1.78 g, 23.6 mmol) and ammonium acetate 
(3.75 g, 39.3 mmol) were added with acetic acid (25 mL) which was stirred to reflux 
for 4 hr. After cooling, water was added until a yellow/orange solid formed, which 
was then left to stir for a further 10 min in an ice bath. This was filtered and washed 
with water as a yellow/orange solid. This was recrystallized with IPA and filtered 
yielding a yellow powder (2.10 g, 47%). Mp. 159-161 °C; 1H NMR (400 MHz, CDCl3) 
δ 8.10 (d, J=13.74 Hz, 1 H), 7.83 (d, J=13.74 Hz, 1 H), 7.04 (d, J=9.16 Hz, 1 H), 
6.79 (d, J=12.36 Hz, 1 H), 3.90 (s, 3 H), 3.91 (s, 3 H). 154.6 (d, J=8.63 Hz); 13C 
NMR (101 MHz, CDCl3) δ 56.3, 57.0, 101.2 (d, J=23.96 Hz), 114.5 (d, J=3.83 Hz), 
116.7 (d, J=3.83 Hz), 134.5, 137.7, 141.8 (d, J=11.50 Hz), 155.5 (d, J=255.91 Hz), 
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Synthesis of 2-(4-fluoro-2,5-dimethoxy-phenyl)ethanamine (44) 
 
In an argon-flushed system, lithium aluminium hydride (2 g, 6 mmol) was suspended 
in anhydrous THF (100 mL) and the solution was stirred thoroughly. 43 (2 g, 8.84 
mmol) was dissolved in THF (50 mL) and was added in slowly, this was stirred for 3 
h at RT then refluxed for 15 min. The remaining LAH was decomposed by water 
followed by NaOH (15%, 2 mL) to precipitate out the basic insolubilities, this was 
then filtered and the filtrate being washed with THF (3 x 40 mL). The organic solution 
was concentrated in vacuo and 2M HCl (20 mL) was added. This was washed with 
DCM (3 x 20 mL) and the aq layer then neutralised with aqueous NaOH. This was 
extracted with DCM (5 x 20 mL), dried with MgSO4 and concentrated in vacuo. The 
amber oil was dissolved with IPA (10 mL), neutralised with conc. HCl (12 M) and 
upon addition of anhydrous ether crystals formed. The salt was recrystallized with 
IPA and filtered yielding a white powder (1.63 g, 93%); Mp. 180-182 °C; 1H NMR 
(400 MHz, CD3OD) δ 6.99 (d, J=9.16 Hz, 1 H), 6.86 (d, J=13.28 Hz, 1 H), 3.81 (s, 3 
H), 3.83 (s, 3 H), 3.08 - 3.16 (m, 2 H), 2.89 - 2.97 (m, 2 H); 13C NMR (101 MHz, 
CD3OD) δ 153.3, 153.5 (d, J=244.41 Hz), 142.7, 121.3 (d, J=3.83 Hz), 118.3 (d, 




71 | P a g e  
 
Synthesis of 2-[2-(2,5-dimethoxyphenyl)ethyl]isoindoline-1,3-dione (45) 
 
With a Dean-Stark set up, phthalic anhydride (11.105 g, 75 mmol) was suspended 
in an excess of toluene and heated to reflux until there was no more water evolution. 
2,5-dimethoxyphenethylamine (10.87 g, 62.5 mmol) was added dropwise and left to 
reflux for 3 hr. This was concentrated in vacuo to a yellow oil that spontaneously 
crystallized to a yellow solid. The pthalimide was further recrystallized with IPA and 
filtered yielding a white powder (14.00 g, 72%); Mp. 110 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.03 (dd, J=5.50, 3.21 Hz, 1 H), 7.92 (dd, J=5.72, 2.98 Hz, 1 H), 7.78 - 
7.85 (m, 2 H), 7.65 - 7.73 (m, 2 H), 6.66 - 6.76 (m, 3 H), 3.95 (t, J=7.10 Hz, 2 H), 
3.67 (s, 3 H), 3.71 (s, 3 H), 2.98 (t, J=7.10 Hz, 2 H); 13C NMR (101 MHz, CD3Cl) δ 
168.2, 153.2, 152.0, 133.7, 132.1, 127.6, 123.0, 116.6, 112.2, 111.0, 55.7, 55.6, 
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Synthesis of 2-[2-(4-iodo-2,5-dimethoxy-phenyl)ethyl]isoindoline-1,3-dione 
(46) 
 
To a solution of 45 (12.76g, 41 mmol) in glacial acetic acid (120 mL), 1 M iodine 
monochloride in acetic acid (61.69 mL, 61.6 mmol) was added dropwise and stirred 
for 1 hr at 40 °C. The solution was poured into water (1500 mL) and extracted with 
DCM (4 x 75 mL) with the organic layers being collected. The organic solution 
washed with sodium dithionite (2 g) in water (150 mL), with the colour changing from 
red to yellow, and concentrated in vacuo to obtain a brown solid. The iodated 
pthalimide was recrystallized with IPA and filtered yielding a white powder (13.53 g, 
76 %); Mp. 147-149°C; 1H NMR (400 MHz, CDCl3) δ 7.78 - 7.86 (m, 2 H), 7.66 - 7.75 
(m, 2 H), 6.65 - 6.77 (m, 3 H), 3.91 - 4.02 (m, 2 H), 3.66 - 3.75 (m, 6 H), 2.98 (t, 
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Synthesis of 2-(4-iodo-2,5-dimethoxy-phenyl)ethanamine (47)  
 
IPA was heated to reflux temperature with 46 (12.2 g, 28 mmol), treated with 
hydrazine hydrate (6 mL, 190 mmol) and refluxed o/n. The solution was left to cool, 
and the solids removed by filtration, washed with EtOH (2 x 20 mL) and the 
combined filtrate concentrated in vacuo. The oily residue treated with conc. HCl (12 
M) produced white crystals. The salt was recrystallized in water (3 mL), filtered, 
washed with IPA and further washed with Et2O to produce a pure white/pink powder 
and filtered yielding (0.85 g, 10%); Mp. 240-242°C; 1H NMR (400 MHz, CD3OD) δ 
7.35 (s, 1 H), 6.86 (s, 1 H), 3.81 (s, 3 H), 3.82 (s, 3 H), 3.14 (t, J=7.33 Hz, 2 H), 2.94 
(t, J=7.33 Hz, 2 H); 13C NMR (101 MHz, CD3OD) δ 154.46, 153.79, 127.33, 123.17, 
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Synthesis of 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (48) 
 
To cooled glacial acetic acid (60 mL), 2,5-dimethoxyphenethylamine (2.905 g, 15.95 
mmol) and nitric acid (10 mL) was stirred with external cooling for 1 hr. The solution 
was poured into water (200 mL), followed by the addition of NaOH (6 M, 300 mL) 
and extracted with DCM (6 x 100 mL). The organic solution was washed with water 
(3 x 200 mL), brine (3 x 200 mL), dried with NaSO4 and concentrated in vacuo to a 
deep red oil. The free base crystallised (2.3961 g, 66%) and no further purification 
required. 1H NMR (400 MHz, CDCl3) δ 7.4 (s, 1 H), 6.9 (s, 1 H), 3.9 (s, 3 H), 3.8 (s, 
3 H), 3.0 (t, J=6.87 Hz, 2 H), 2.8 (t, J=6.87 Hz, 2 H), 1.5 (br. s., 3 H); 13C NMR (101 
MHz, CDCl3) δ 150.9, 147.6, 136.6, 116.3, 107.5, 57.1, 56.0, 41.7, 35.1; GC-MS 
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General procedure A - for the synthesis of secondary amines 
Adapting Hansen’s synthesis of NBOMe’s, Et3N (1.0 eq.) was added to a 
suspension of phenethylamine hydrochloride (1.0 mmol) and aldehyde (1.1 mmol) 
in 10 mL EtOH. The reaction was stirred until the imine formation was complete 
according to TLC. NaBH4 (2.0 mmol) was added slowly and the reaction stirred for 
a further 30 mins. The reaction mixture was concentrated in vacuo and the residue 
portioned between DCM and water (30 mL, 1:1). The organic layer was isolated and 
the aqueos layer extracted twice more with DCM (2 x 15 mL). The combined layers 
were dried over MgSO4, filtered and concentrated in vacuo to an amber residue. 
The residue was purified by flash chromatography (DCM/MeOH/NH3 98:2:0.04). 
The purified free base was then dissolved in EtOH (2 mL) followed by ethanolic HCl 
(1 M, 2 mL) and the solution then further diluted with EtOH until crystals formed. The 





Using general procedure A, the target compound was obtained with 28 (0.26 g, 1 
mmol) and 2-methoxybenzaldehyde (0.15 g, 1.1 mmol). The salt was filtered 
yielding a white powder (0.18 g, 47%); Mp. 178-180 °C; 1H NMR (400 MHz, CD3OD) 
δ 7.43 - 7.49 (m, 1 H), 7.39 (dd, J=7.56, 1.60 Hz, 1 H), 7.17 (s, 1 H), 7.09 (d, J=8.24 
Hz, 1 H), 7.00 - 7.06 (m, 1 H), 6.98 (s, 1 H), 4.25 (s, 2 H), 3.89 (s, 3 H), 3.83 (s, 3 
H), 3.79 (s, 3 H), 3.18 - 3.26 (m, 2 H), 2.99 - 3.07 (m, 2 H); 13C NMR (101 MHz, 
CD3OD) δ 157.5, 151.5, 149.4, 131.5, 130.7, 125.5, 120.3, 119.7, 115.9, 114.9, 
111.1, 108.9, 56.6, 56.2, 55.6, 45.7, 44.7, 26.3. GC-MS 9.506 min, m/z 121. Data 
corresponds to the spectroscopic assignments reported by M. Hansen et al.142  
 
 





Using general procedure A, the target compound was obtained with 31 (0.22g g, 1 
mmol) and 2-methoxybenzaldehyde (0.15 g, 1.1 mmol). The salt was filtered 
yielding a white powder (0.09 g, 26%); Mp. 180-181 °C; 1H NMR (400 MHz, CD3OD) 
δ 7.43 - 7.49 (m, 1 H), 7.37 - 7.41 (m, 1 H), 7.10 (d, J=8.24 Hz, 1 H), 7.00 – 7.05 
(m, 1 H), 7.04 (s, 1 H) 6.98 (s, 1 H), 4.25 (s, 2 H), 3.89 (s, 3 H), 3.84 (s, 3 H), 3.79 
(s, 3 H), 3.19 - 3.26 (m, 2 H), 3.00 - 3.06 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 
ppm 159.5, 153.1, 150.8, 132.9, 125.3, 122.9, 122.2, 120.4, 116.7, 114.5, 112.2, 
57.5, 56.8, 56.4, 48.1, 48.1, 28.3, 24.4; GC-MS 9.225 min, m/z 321. Data 











Using general procedure A, the target compound was obtained with 34 (0.2 g, 1 
mmol) and 2-methoxybenzaldehyde (0.15 g, 1.1 mmol). The salt was filtered 
yielding a white powder (0.14 g, 44%); 1H NMR (400 MHz, CD3OD) δ 7.2 - 7.3 (m, 
1 H), 7.2 (dd, J=7.33, 1.37 Hz, 1 H), 6.9 - 7.0 (m, 2 H), 6.7 (s, 1 H), 6.7 (s, 1 H), 3.8 
(s, 2 H), 3.7 (s, 3 H), 3.7 (s, 3 H), 3.7 (s, 3 H), 2.8 (t, J=3.89 Hz, 4 H), 2.2 (s, 3 H); 
13C NMR (101 MHz, CD3OD) δ 159.3, 153.1, 152.8, 131.8, 130.6, 126.7, 126.5, 
125.9, 121.6, 115.0, 114.2, 111.6, 56.5, 56.5, 55.8, 49.2, 30.6, 16.4. Data 









Using general procedure A, the target compound was obtained with 41 (0.42 g, 2 
mmol) and 2-methoxybenzaldehyde (0.3 g, 2.2 mmol). The salt was filtered yielding 
a white powder (0.31 g, 47%); 1H NMR (400 MHz, CD3OD) δ 9.4 (br. s., 2 H), 7.4 
(dd, J=7.56, 1.60 Hz, 1 H), 7.3 (td, J=7.90, 1.60 Hz, 1 H), 7.0 (t, J=7.33 Hz, 1 H), 
6.8 (d, J=8.24 Hz, 1 H), 6.7 (s, 1 H), 6.7 (s, 1 H), 4.1 (t, J=5.27 Hz, 2 H), 3.7 (s, 3 
H), 3.7 (s, 3 H), 3.6 (s, 3 H), 3.0 - 3.2 (m, 4 H), 2.5 - 2.6 (m, 2 H), 1.2 (t, J=7.33 Hz, 
3 H); 13C NMR (101 MHz, CD3OD) δ 159.3, 153.0, 152.7, 133.0, 131.7, 130.6, 126.6, 
126.1, 121.6, 114.5, 113.6, 111.6, 56.6, 56.5, 55.9, 49.8, 49.2, 30.6, 24.6, 15.2. Data 









Using general procedure A, the target compound was obtained with 44 (0.21 g, 1.0 
mmol) and 2-methoxybenzaldehyde (0.15 g, 1.1 mmol). The salt was filtered 
yielding a white powder (0.11 g, 64%); Mp. 141-144°C; 1H NMR (400 MHz, CD3OD) 
δ 7.46 (ddd, J=8.36, 7.44, 1.60 Hz, 1 H), 7.38 (dd, J=7.33, 1.83 Hz, 1 H), 7.11 (d, 
J=8.24 Hz, 1 H), 6.97 - 7.07 (m, 2 H), 6.87 (d, J=12.82 Hz, 1 H), 4.24 (s, 2 H), 3.90 
(s, 3 H), 3.83 (s, 3 H), 3.78 (s, 3 H), 3.17 - 3.24 (m, 2 H), 2.97 - 3.03 (m, 2 H); 13C 
NMR (101 MHz, CD3OD) δ 158.0, 151.7, 141.3, 131.4, 120.7, 119.6, 118.9, 116.8, 
110.7, 100.6, 100.3, 56.4, 55.3, 54.9, 46.7, 46.6, 26.5, 22.9; GC-MS 8.692 min, m/z 











Using general procedure A, the target compound was obtained with 47 (0.31 g, 1 
mmol) and 2-methoxybenzaldehyde (0.15 g, 1.1 mmol). The salt was filtered 
yielding a white powder (0.26 g, 61%); Mp. 161-163 °C; 1H NMR (400 MHz, CD3OD) 
δ 7.43 - 7.49 (m, 1 H), 7.39 (dd, J=7.56, 1.60 Hz, 1 H), 7.34 (s, 1 H), 7.09 (d, J=8.24 
Hz, 1 H), 7.00 - 7.05 (m, 1 H), 6.87 (s, 1 H), 4.24 (s, 2 H), 3.89 (s, 3 H), 3.82 (s, 3 
H), 3.78 (s, 3 H), 3.19 - 3.26 (m, 2 H), 2.99 - 3.05 (m, 2 H); 13C NMR (101 MHz, 
CD3OD) δ 157.7, 152.5, 151.9, 132.0, 131.1, 125.9, 121.5, 120.9, 118.3, 114.0, 
110.4, 83.8, 57.1, 55.8, 55.5, 46.4, 44.9, 28.0; GC-MS 9.851 min, m/z 121. Data 










Using general procedure A, the target compound was obtained with 48 (0.47 g, 2 
mmol) and 2-methoxybenzaldehyde (0.31 g, 2.2 mmol). The salt was filtered 
yielding a white powder (0.39 g, 74%); 1H NMR (400 MHz, CD3OD) δ 7.4 (s, 1 H), 
7.2 (t, J=8.01 Hz, 1 H), 7.2 (d, J=7.33 Hz, 1 H), 7.0 (s, 1 H), 6.9 - 6.9 (m, 2 H), 3.9 
(s, 3 H), 3.8 (s, 3 H), 3.7 (s, 5 H), 2.8 - 2.9 (m, 2 H), 2.8 - 2.8 (m, 2 H); 13C NMR (101 
MHz, CD3OD) δ 159.5, 152.3, 148.5, 140.1, 133.1, 132.9, 122.2, 120.4, 118.2, 









Using general procedure A, the target compound was obtained with 28 (0.26 g, 1 
mmol) and nicotinaldehyde (0.10 mL, 1.1 mmol). The salt was filtered yielding a 
white powder (0.01 g, 3%); 1H NMR (400 MHz, CD3OD) δ 9.2 (s, 1 H), 9.0 (d, J=5.50 
Hz, 1 H), 8.9 (d, J=8.24 Hz, 1 H), 8.2 (dd, J=8.24, 5.95 Hz, 1 H), 7.2 (s, 1 H), 7.1 (s, 
1 H), 4.6 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.1 - 3.1 (m, 2 H); 13C 
NMR (101 MHz, CD3OD) δ 153.5, 151.6, 150.4, 149.0, 138.7, 137.1, 129.6, 125.4, 











Using general procedure A, the target compound was obtained with 31 (0.32 g, 2 
mmol) and nicotinaldehyde (0.2 mL, 2.2 mmol). The salt was filtered yielding a white 
powder (0.2024 g, 44%); 1H NMR (400 MHz, CD3OD) δ 9.2 (s, 1 H), 9.0 (d, J=5.95 
Hz, 1 H), 8.8 - 8.9 (m, 2 H), 8.2 (dd, J=8.01, 5.72 Hz, 1 H), 7.1 (s, 1 H), 7.0 (s, 1 H), 
4.6 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.1 - 3.1 (m, 2 H); 13C NMR 
(101 MHz, CD3OD) δ 153.02, 150.33, 145.86, 145.49, 144.81, 128.43, 128.30, 
125.02, 122.52, 116.60, 114.22, 61.06, 57.47, 56.76, 48.77, 48.59, 28.36; GC-MS 










Using general procedure A, the target compound was obtained with 34 (0.2 g, 1 
mmol) and nicotinaldehyde (0.1 mL, 1.1 mmol). The salt was filtered yielding a white 
powder (0.2 g, 69%); 1H NMR (400 MHz, CD3OD) δ 9.1 (br. s., 1 H), 9.0 (d, J=4.58 
Hz, 1 H), 8.8 (d, J=7.78 Hz, 1 H), 8.2 (t, J=6.64 Hz, 1 H), 6.8 (s, 1 H), 6.8 (s, 1 H), 
4.5 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.4 (t, J=7.56 Hz, 2 H), 3.1 (t, J=7.56 Hz, 2 H), 
2.2 (s, 3 H); 13C NMR (101 MHz, CD3OD) δ 153.4, 152.7, 149.5, 145.1, 144.3, 133.4, 











Using general procedure A, the target compound was obtained with 41 (0.31 g, 1.5 
mmol) and nicotinaldehyde (0.15 mL, 1.65 mmol). The salt was filtered yielding a 
white powder (0.22 g, 49%); 1H NMR (400 MHz, CD3OD) δ 9.1 (s, 1 H), 9.0 (d, 
J=5.50 Hz, 1 H), 8.9 (d, J=8.24 Hz, 1 H), 8.2 (dd, J=8.24, 5.95 Hz, 1 H), 6.9 (s, 1 H), 
6.8 (s, 1 H), 4.6 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.4 (t, J=7.56 Hz, 2 H), 3.0 - 3.1 
(m, 2 H), 2.6 (q, J=7.33 Hz, 2 H), 1.2 (t, J=7.56 Hz, 3 H); 13C NMR (101 MHz, 
CD3OD) δ 152.9, 149.6, 145.0, 144.2, 134.2, 133.5, 129.0, 123.1, 114.7, 113.7, 










Using general procedure A, the target compound was obtained with 44 (0.4 g, 2 
mmol) and nicotinaldehyde (0.2 mL, 2.2 mmol). The salt was filtered yielding a white 
powder (0.1597 g, 28%); 1H NMR (400 MHz, CD3OD) δ 9.2 (s, 1 H), 9.0 (d, J=5.50 
Hz, 1 H), 8.9 (d, J=8.24 Hz, 1 H), 8.2 (dd, J=8.01, 5.72 Hz, 1 H), 7.1 (d, J=9.16 Hz, 
1 H), 6.9 (d, J=12.82 Hz, 1 H), 4.6 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 
H), 3.0 - 3.1 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 153.3 (d, J=8.63 Hz), 153.4 
(d, J=244.41 Hz), 149.9, 144.9, 144.0, 142.7, 142.6, 142.7 (d, J=10.54 Hz), 133.5, 
129.0, 120.8 (d, J=3.83 Hz), 118.3, 118.3, 118.3 (d, J=2.88 Hz), 101.9 (d, J=23.00 








Using general procedure A, the target compound was obtained with 47 (0.64 g, 1.5 
mmol) and nicotinaldehyde (0.15 mL, 1.65 mmol). The salt was filtered yielding a 
white powder (0.48 g, 81%); 1H NMR (400 MHz, CD3OD) δ 9.0 (s, 1 H), 8.8 (d, 
J=4.58 Hz, 1 H), 8.5 (d, J=8.24 Hz, 1 H), 7.9 (dd, J=8.24, 5.50 Hz, 1 H), 7.3 (s, 1 H), 
6.9 (s, 1 H), 4.5 (s, 2 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.4 (t, J=8.24 Hz, 2 H), 3.1 (t, 
J=7.33 Hz, 2 H); 13C NMR (101 MHz, CD3OD) δ 154.4, 153.7, 147.7, 147.1, 145.8, 
131.8, 127.7, 126.9, 123.2, 115.1, 85.1, 57.7, 56.8, 49.0, 28.8; GC-MS 9.660 min, 








Using general procedure A, the target compound was obtained with 48 (0.45 g, 2 
mmol) and nicotinaldehyde (0.2 mL, 2.2 mmol). The salt was filtered yielding a white 
powder (0.29 g, 46%); 1H NMR (400 MHz, CD3OD) δ 8.5 (d, J=2.29 Hz, 1 H), 8.4 
(dd, J=5.04, 1.37 Hz, 1 H), 7.8 (dt, J=8.13, 1.89 Hz, 1 H), 7.4 - 7.5 (m, 2 H), 7.1 (s, 
1 H), 4.7 (s, 1 H), 3.9 (s, 3 H), 3.8 (s, 2 H), 3.8 (s, 3 H), 2.9 (ddd, J=8.24, 6.41, 1.83 
Hz, 2 H), 2.8 (ddd, J=8.36, 6.53, 2.06 Hz, 2 H); 13C NMR (101 MHz, CD3OD) δ 
152.3, 151.2, 150.8, 148.5, 141.0, 140.1, 132.9, 129.7, 126.1, 118.2, 108.7, 61.4, 










Using general procedure A, the target compound was obtained with 28 (0.52 g, 2 
mmol) and 5-flouronicotinaldehyde (0.28 g, 2.2 mmol). The salt was filtered yielding 
a white powder (0.3022 g, 41%); 1H NMR (400 MHz, CD3OD) δ 8.9 - 9.0 (m, 3 H), 
8.8 (s, 1 H), 8.5 - 8.6 (m, 2 H), 7.2 (s, 1 H), 7.0 (s, 1 H), 4.9 (s, 1 H), 4.5 (s, 2 H), 3.8 
(s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.1 - 3.1 (m, 2 H); 13C NMR (101 MHz, 
CD3OD) δ 162.0 (d, J=253.99 Hz), 153.4, 151.8, 144.3 (d, J=3.83 Hz), 138.0, 136.5 











Using general procedure A, the target compound was obtained with 31 (0.33 g, 1.5 
mmol) and 5-flouronicotinaldehyde (0.2127 g, 1.65 mmol). The salt was filtered 
yielding a white powder (0.1744 g, 36%); 1H NMR (400 MHz, CD3OD) δ 9.0 (s, 1 H), 
8.9 (s, 1 H), 8.5 (d, J=8.24 Hz, 1 H), 7.1 (s, 1 H), 7.0 (s, 1 H), 4.5 (s, 2 H), 3.8 (s, 3 
H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.0 - 3.1 (m, 2 H); 13C NMR (101 MHz, CD3OD) 
δ 161.4 (d, J=254.95 Hz), 153.3, 150.5, 146.7 (d, J=3.83 Hz), 137.2 (d, J=24.92 Hz), 
128.9, 124.8 (d, J=18.21 Hz), 123.2 (d, J=18.21 Hz), 121.6, 116.5, 114.1, 61.8, 57.4, 










Using general procedure A, the target compound was obtained with 34 (0.2 g, 1 
mmol) and 5-flouronicotinaldehyde (0.14 g, 1.1 mmol). The salt was filtered yielding 
a white powder (0.19 g, 61 %); 1H NMR (400 MHz, CD3OD) δ 9.0 (br. s., 1 H), 8.9 
(s, 1 H), 8.5 (d, J=8.70 Hz, 1 H), 6.8 (s, 1 H), 6.8 (s, 1 H), 4.5 (s, 2 H), 3.8 (s, 3 H), 
3.8 (s, 3 H), 3.3 (t, J=1.00 Hz, 2 H), 3.0 - 3.1 (m, 2 H), 2.2 (s, 3 H); 13C NMR (101 
MHz, CD3OD) δ 161.0 (d, J=254.95 Hz), 153.1, 152.7, 146.8 (d, J=3.83 Hz), 138.7, 
137.5 (d, J=24.92 Hz), 126.6, 126.5, 125.0 (d, J=18.21 Hz), 115.0, 114.2, 56.5, 56.5, 









Using general procedure A, the target compound was obtained with 41 (0.31, 1.5 
mmol) and 5-flouronicotinaldehyde (0.21 g, 1.65 mmol). The salt was filtered 
yielding a white powder (0.12 g, 25 %); 1H NMR (400 MHz, CD3OD) δ 9.0 (s, 1 H), 
8.9 (s, 1 H), 8.5 (d, J=8.24 Hz, 1 H), 6.9 (s, 1 H), 6.8 (s, 1 H), 4.5 (s, 2 H), 3.8 (s, 3 
H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.0 - 3.1 (m, 2 H), 2.6 (q, J=7.48 Hz, 2 H), 1.2 (t, 
J=7.56 Hz, 3 H); 13C NMR (101 MHz, CD3OD) δ 161.4 (d, J=256.87 Hz), 152.9, 
144.5 (d, J=3.83 Hz), 136.7 (d, J=29.71 Hz), 134.2, 133.7, 133.6, 132.6 (d, J=19.17 










Using general procedure A, the target compound was obtained with 44 (0.28 g, 2 
mmol) and 5-flouronicotinaldehyde (0.28 g, 2.2 mmol). The salt was filtered yielding 
a white powder (0.16 g, 27%); 1H NMR (400 MHz, CD3OD) δ 9.0 (br. s, 1 H), 9.0 (s, 
1 H), 8.6 (d, J=8.24 Hz, 1 H), 7.1 (d, J=9.62 Hz, 1 H), 6.9 (d, J=12.82 Hz, 1 H), 4.5 
(s, 2 H), 3.8 - 3.8 (m, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.0 - 3.1 (m, 2 H); 13C 
NMR (101 MHz, CD3OD) δ 161.5 (d, J=253.04 Hz), 153.2 (d, J=8.63 Hz), 153.4 (d, 
J=245.37 Hz), 143.9 (d, J=3.83 Hz), 142.7 (d, J=10.54 Hz), 136.0 (d, J=33.55 Hz), 
134.0 (d, J=19.17 Hz), 132.8 (d, J=19.17 Hz), 120.8 (d, J=3.83 Hz), 118.3 (d, J=2.88 











Using general procedure A, the target compound was obtained with 47 (0.80 g, 2 
mmol) and 5-flouronicotinaldehyde (0.28 g, 2.2 mmol). The salt was filtered yielding 
a white powder (0.3841 g, 46%); 1H NMR (400 MHz, CD3OD ) δ 8.9 (s, 1 H), 8.8 (d, 
J=6.87 Hz, 1 H), 7.8 (d, J=6.87 Hz, 1 H), 7.3 (s, 1 H), 7.0 (s, 1 H), 4.4 (s, 2 H), 4.3 
(s, 3 H), 3.8 (s, 6 H), 3.4 (t, J=7.56 Hz, 2 H), 3.1 (t, J=6.41 Hz, 2 H); 13C NMR (101 
MHz, CD3OD ) δ 161.4 (d, J=261.66 Hz), 154.5, 153.7, 145.0 (d, J=3.83 Hz), 137.2 
(d, J=29.71 Hz), 133.2, 131.9 (d, J=19.17 Hz), 126.8, 123.2, 115.1, 85.1, 57.7, 56.8, 










Using general procedure A, the target compound was obtained with 48 (0.45 g, 2 
mmol) and 5-flouronicotinaldehyde (0.28 g, 2.2 mmol). The salt was filtered yielding 
a white powder (0.41 g, 61%); 1H NMR (400 MHz, CD3OD) δ 8.9 (br. s, 1 H), 8.8 (s, 
1 H), 8.3 (d, J=8.24 Hz, 1 H), 7.5 (s, 1 H), 7.3 (s, 1 H), 4.5 (s, 2 H), 3.9 (s, 3 H), 3.9 
(s, 3 H), 3.4 (t, J=7.56 Hz, 2 H), 3.1 - 3.2 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 
161.4 (d, J=255.91 Hz), 152.4, 148.6, 146.7 (d, J=3.83 Hz), 145.0, 139.1, 137.4 (d, 










Using general procedure A, the target compound was obtained with 28 (0.52 g, 2 
mmol) and 4-methoxypyridine-3-carbaldehyde (0.30 g, 2.2 mmol). The salt was 
filtered yielding a white powder (0.5067 g, 67%); 1H NMR (400 MHz, CD3OD) δ 8.9 
(s, 1 H), 8.9 (d, J=6.87 Hz, 1 H), 7.8 (d, J=7.33 Hz, 1 H), 7.2 (s, 1 H), 7.0 (s, 1 H), 
4.4 (s, 2 H), 4.3 (s, 3 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.0 - 3.2 (m, 2 
H); 13C NMR (101 MHz, CD3OD) δ 172.7, 153.4, 151.8, 146.5, 144.8, 125.9, 121.2, 









Using general procedure A, the target compound was obtained with 31 (0.32 g, 1.5 
mmol) and 4-methoxypyridine-3-carbaldehyde (0.23 g, 1.65 mmol). The salt was 
filtered yielding a white powder (0.1697 g, 34%); 1H NMR (400 MHz, CD3OD) δ 8.9 
(s, 1 H), 8.9 (dd, J=6.87, 1.37 Hz, 1 H), 7.8 (d, J=7.33 Hz, 1 H), 7.1 (s, 1 H), 7.1 (s, 
1 H), 4.4 (s, 2 H), 4.3 (s, 3 H), 3.9 (s, 3 H), 3.8 (s, 3 H), 3.4 (dd, J=8.93, 6.64 Hz, 2 
H), 3.1 - 3.1 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 172.6, 153.2, 150.8, 146.6, 









Using general procedure A, the target compound was obtained with 34 (0.2 g, 1.1 
mmol) and 4-methoxypyridine-3-carbaldehyde (0.15 g, 1.1 mmol). The salt was 
filtered yielding a white powder (0.17 g, 53%); 1H NMR (400 MHz, CD3OD) δ 8.9 (s, 
1 H), 8.9 (dd, J=1.00 Hz, 1 H), 7.8 (d, J=6.87 Hz, 1 H), 6.8 (s, 1 H), 6.8 (s, 1 H), 4.4 
(s, 2 H), 4.3 (s, 3 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 - 3.4 (m, 2 H), 3.0 - 3.1 (m, 2 H), 
2.2 (s, 3 H); 13C NMR (101 MHz, CD3OD) δ 166.3, 153.1, 152.8, 151.9, 151.1, 126.7, 










Using general procedure A, the target compound was obtained with 41 (0.31 g, 1.5  
mmol) and 4-methoxypyridine-3-carbaldehyde (0.23 g, 1.65 mmol). The salt was 
filtered yielding a white powder (0.17 g, 34 %); 1H NMR (400 MHz, CD3OD) δ 8.9 
(s, 1 H), 8.9 (d, J=6.87 Hz, 1 H), 7.8 (d, J=6.87 Hz, 1 H), 6.9 (s, 1 H), 6.8 (s, 1 H), 
4.4 (s, 2 H), 4.3 (s, 3 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 (t, J=1.00 Hz, 2 H), 3.1 (t, 
J=7.79 Hz, 2 H), 2.6 (q, J=7.63 Hz, 2 H), 1.2 (t, J=7.56 Hz, 3 H); 13C NMR (101 MHz, 
CD3OD) δ 172.7, 152.9, 152.9, 146.5, 144.8, 134.2, 123.1, 121.2, 114.7, 113.7, 









Using general procedure A, the target compound was obtained with 44 (0.4 g, 2  
mmol) and 4-methoxypyridine-3-carbaldehyde (0.3 g, 1.65 mmol). The salt was 
filtered yielding a white powder (0.19 g, 31%); 1H NMR (400 MHz, CD3OD) δ 8.9 (s, 
1 H), 8.9 (d, J=6.87 Hz, 1 H), 7.8 (d, J=7.33 Hz, 1 H), 7.1 (d, J=9.16 Hz, 1 H), 6.9 
(d, J=13.28 Hz, 1 H), 4.4 (s, 2 H), 4.3 (s, 3 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.3 (d, J=7.79 
Hz, 2 H), 3.0 - 3.1 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 172.7, 153.3, 146.6, 











Using general procedure A, the target compound was obtained with 47 (0.39 g, 1 
mmol) and 4-methoxypyridine-3-carbaldehyde (0.15 g, 1.1 mmol). The salt was 
filtered yielding a white powder (0.3022 g, 71%); 1H NMR (400 MHz, (CD3)2SO) δ 
9.9 (br. s., 2 H), 9.0 (s, 1 H), 8.9 (d, J=6.41 Hz, 1 H), 7.7 (d, J=6.87 Hz, 1 H), 7.3 (s, 
1 H), 6.9 (s, 1 H), 4.3 (br. s., 2 H), 4.1 (s, 3 H), 3.8 (s, 3 H), 3.8 (s, 3 H), 3.4 - 3.6 (m, 
3 H), 3.2 (br. s., 2 H), 2.9 - 3.0 (m, 2 H); 13C NMR (101 MHz, (CD3)2SO) δ 169.6, 
152.0, 151.8, 144.6, 143.5, 126.2, 121.4, 119.5, 113.8, 109.8, 84.0, 58.3, 56.9, 56.3, 









Using general procedure A, the target compound was obtained with 48 (0.45 g, 2 
mmol) and 4-methoxypyridine-3-carbaldehyde (0.30 g, 2.2 mmol). The salt was 
filtered yielding a white powder (0.32 g, 47%); 1H NMR (400 MHz, CD3OD) δ 8.9 (s, 
1 H), 8.9 (d, J=6.87 Hz, 1 H), 7.8 (d, J=6.87 Hz, 1 H), 7.5 (s, 1 H), 7.3 (s, 1 H), 4.5 
(s, 2 H), 4.3 (s, 3 H), 3.9 (s, 3 H), 3.9 (s, 3 H), 3.4 - 3.5 (m, 2 H), 3.2 - 3.2 (m, 2 H) 
13C NMR (101 MHz, CD3OD) δ 172.1, 151.7, 147.8, 145.8, 144.2, 139.5, 132.3, 




103 | P a g e  
 
3 Chapter 3 – Synthesis 
3.1 Introduction 
To synthesise the NBOMe and the PET imaging replacement compounds, a variety 
of reactions were required to get to the substituted phenethylamines, which would 
then be used as the starting material for the reductive alkylation step. Shulgin’s book 
PIHKAL (Phenethylamines I have known and loved)143 was used for the 
phenethylamine synthesis steps but some have been modified to maximise 
efficiency (Scheme 7). For example, the Hansen et al.37 method was used to 
synthesise the NBOMe’s, NPyr’s, NPF’s and NPOMe’s.  
 
Scheme 7 - Reaction scheme for NBOMe compounds (11) and novel compounds 
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Figure 11 - Structures of NBOMe’s (11, X = F, Cl, Br, I, Me, Et, NO2), PET imaging 
agents (cimbi-5, 20;cimbi-36, 21) and NPOMe’s (26, X = F, Cl, Br, I, Me, Et, NO2)  
 
The NPOMe’s were the primary focus of this project as the similarity in structure 
with the NBOMe’s and cimbi-5/36 (Figure 11) shows the real potential of replacing 
the imaging agents with a more stable drug. With positive biological assay results, 
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3.2 Synthesis of 2-(4-bromo-2,5-dimethoxy-phenyl)ethanamine (2C-B, 28) 
 
Scheme 8 - Synthetic scheme for the synthesis of 2C-B (28) 
 
The synthesis of 28 (Scheme 8) was achieved using a one-step reaction as 2,5-
dimethoxyphenethylamine (Scheme 9) was commercially available, so a 
bromination step was the easiest route. It was also noted that there was no 
recrystallization required as it was found that washing with ether (Figure 12) and 
cold acetone (Figure 13) purified the compound. Washing the powder with cold 
acetone decolourised the powder from an off white to white, furthermore, when left 
overnight this led to the formation of crystals. The crystals were further washed with 
cold acetone and characterised; the 1H NMR spectrum of these crystals matched 
that of the powder obtained. When comparing the data to Kanamori et al,132 two 
singlet peaks in the 1H NMR aromatic region confirmed the bromination was 
successful and along with the GC-MS data possessing one peak (RT – 6.856 min), 
these data indicated a clean synthesis of 2C-B. 
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Figure 12 - 1H NMR (CD3OD, 400 MHz) spectra of 28.HCl (30 mg mL-1) after washing with H2O and Et2O
 
 
107 | P a g e  
 
 
Figure 13 - 1H NMR (CD3OD, 400 MHz) spectrum of 28.HCl (30 mg mL-1) after washing with H2O, Et2O and acetone
 
 
108 | P a g e  
 
3.3 Synthesis of 2-(4-chloro-2,5-dimethoxy-phenyl)ethanamine (2C-C, 31)  
 
Scheme 10 - Synthetic scheme of 2C-C (31); a) HMTA, TFA, reflux, 15 h, 55 %; b) 
nitromethane, ammonium acetate, AcOH, reflux, 4 h, 34 %; c) LiAH4, THF, RT, 3 h, 
50 % 
 
Following Shulgin’s methodology (Scheme 10), the Duff formylation was utilised for 
the synthesis of 29. Other formylating methods have been applied within the 
synthesis of other compounds (Rieche, Vilsmeier-Haack) but due to the inductive 
effect being larger than the mesomeric effects, these were not attempted. These 
mesomeric effects decrease the π-electron density within the ring making 
substitution reactions difficult. Therefore, a Duff formylation was utilised with 
hexamethylenetetramine (HMTA) and TFA being used as the formylating group. The 
proposed mechanism for the Duff formylation is shown in Scheme 11. 
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After comparison with the spectral data from Bloomer et al.134 the aldehyde peak 
was found at 10.39 ppm whereas Bloomer reported it at 10.32 ppm. The difference 
of 0.07 ppm was found throughout the data but peak shapes and integration values 
all matched the previously reported data. 
 
The Henry (nitro-aldol) reaction was utilised for five aldehydes (methyl, ethyl, fluoro, 
chloro and iodo derivatives) to be synthesised (Scheme 12). These compounds 
have not been produced before and so no data is available to compare to. Therefore, 
it is the first documented synthesis of all the substituted beta-nitrostyrenes.  
 
 
Scheme 12 - Proposed reaction mechanism of the Henry reaction followed by 
dehydration (X = Me, Et, Cl, F) 
 
When looking at the 1H NMR data for the β-nitrostryrenes (30 shown in Figure 14), 
the dehydration step leaves these compounds in the trans-formation. This is shown 
by the J-couplings from the vicinal hydrogens being 14 Hz (between 11 – 18 Hz and 
typically 16 Hz) whereas vicinal cis-coupling would be in the region of 6 – 14 Hz and 
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Figure 14 - 1H NMR spectrum of 30 
 
The Shulgin method of lithium aluminium hydride (LAH) reductions had to be 
modified to maximise the yields, as to start with the LAH was stirred in anhydrous 
ether and cooled, to which was slowly added nitrostyrene dissolved in THF, followed 
by stirring at RT overnight and subsequent 15 min reflux. After forming the 
aluminium salts, this was filtered and washed with THF and concentred in vacuo. 
The oil was dissolved in IPA, acidified with 5 drops of conc. HCl (12 M) and 
anhydrous ether added to precipitate the phenethylamine as the salt. What was 
found is that this method was not reliable as the phenethylamine would not 
precipitate. This was modified by stirring the LAH with THF at RT and after the 
concentrating the THF in vacuo, an acid base work up was used to purify and isolate 
the phenethylamine free-base. After concentration of the organic phase, the same 
HCl salt formation method was used which precipitated out the salts with no 
impurities. Despite being in harsh conditions, this method reduced both the alkene 
and nitro group effectively to the phenethylamine target (Figure 15). The alkene 
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peaks at 8.08 and 7.87 ppm both shifted upfield to 3.14 and 2.95 ppm indicating 
methylene peaks are present (triplet splitting pattern with a J-coupling of 7.33 Hz).  
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Figure 15 - 1H NMR (CD3OD, 400 MHz) spectrum of 31.HCl
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3.4 Synthesis of 2-(2,5-dimethoxy-4-methyl-phenyl)ethanamine (2C-D, 34) 
 
Scheme 13 – Synthetic scheme of 2C-D (34); a) POCl3, N-methylformanilide, RT, 2 
h, 97 %; b) nitromethane, ammonium acetate, acetic acid, reflux, 3 h, 66 %; c) LAH, 
THF, RT, 3 h, 14 % 
 
34 was prepared via a three-step synthetic strategy (Scheme 13), which employed 
a sequential Vilsmeier-Haack reaction (Scheme 14, Scheme 15), Henry reaction 
(Scheme 12) followed by a LAH reduction. With the Vilsmeier-Haack reaction, the 
first step was to form the Vilsmeier reagent in situ (Scheme 14) before proceeding 
to the second step.  
 
 
Scheme 14 - Reaction mechanism of the formation of the Vilsmeier reagent 
 
The second step had to be monitored carefully as leaving to stir for too long would 
lead to the solution solidifying when cooled, and would not turn back to a solution 
when reheated. Taking off the heat source to cool down was necessary due to the 
reaction being exothermic as well as the evolution of HCl gas (Scheme 14). 
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Comparison of the data with Miyawaki et al.135 indicate five peaks being present in 
the 1H NMR corresponding to the five groups of protons (Figure 16). 
 
Scheme 15 - Reaction mechanism of the Vilsmeier reagent with 2,5-
dimethoxytoluene (R = phenyl) 
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Figure 16 - 1H NMR (CD2Cl2, 400 MHz) spectrum of 32
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3.5 Synthesis of 2-(4-ethyl-2,5-dimethoxy-phenyl)ethanamine (2C-E, 34) 
 
Scheme 16 - Synthetic route of 2C-E (34); (a) acetyl chloride, aluminium chloride, 
DCM, RT, 1 h, 83%; (b) KOH, triethylene glycol, hydrazine hydrate (40 %), 150°C, 
4 h, 85%; (c) iodomethane, KOH, DMSO, 40°C, 1 h, 95 – 99%; (d) tin (IV) chloride, 
dichloromethyl methyl ether, anhydrous DCM, 0°C – RT, 1 h, 83%; (e) nitromethane, 
ammonium acetate, 100°C, 4 h, 29%; (f) LAH, anhydrous THF, RT, 3 h, 50%. 
 
For the synthesis of 41, a five step route was employed (Scheme 16). The first three 
reactions were performed on a smaller scale to monitor the yields as typically when 
performing nitro-aldol reactions the yields are 50% or less and the LAH yield is less 
than 20%. So, to maximise the amount of phenethylamine, 25 g of starting material 
(1,4-dimethoxybenzene) was used to result in 3 g of 41. During the small-scale 
synthesis, it was noted in the acylation that a hydroxylated side product was made 
(Figure 17) which was seen after purification of the desired compound (35) by 
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Figure 17 - Products after the Friedel-Crafts acylation; 2,5-dimethoxyacetophenone 
(35) and 2-hydroxy-5-methoxyacetophenone (36) 
 
The hydroxylated compound was then methylated with iodomethane to produce 35 
to be used in the Wolff-Kishner reduction. For the Wollf-Kishner reduction (Scheme 
17), a Dean-Stark set up was used following the Huang-Minlon144 modification as 
this would remove water and excess hydrazine from the reaction vessel, allowing 
the reaction to reach a temperature of 200°C. After extraction with DCM, the organic 
phase yielded 15% of 1-ethyl-2,5-dimethoxybenzene. Following Shulgin’s 
method,143 it states that acidification of the aqueous phase followed by extraction 
with DCM would leave 2-ethyl-5-methoxyphenol (38, 87 %) which was then 
methylated with iodomethane to produce 37 (85 %). 
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Figure 18 - 1H NMR (CDCl3, 400 MHz) spectrum of 35 
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Figure 19 - 1H NMR (CDCl3, 400 MHz) spectrum of 37 
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This series of compounds were synthesised following Shulgin methodology143 with 
two purification methods used. Vacuum distillation was employed as the 
purification method of 35 due to high amount of crude product at the end of the 
reaction. As shown in Figure 18, the aromatic region of 35 shows two doublets and 
a doublet of doublets. Theoretically, there should be a singlet and two doublets. 
When looking at the J-coupling values of these peaks (Table 5), ortho H-H J-
couplings occur between 6 – 9 Hz, meta J-coupling between 2 – 3 Hz and para J-
coupling between 0 – 1 Hz. As the J values fit into this criteria, assigning 
hydrogens can be achieved without further NMR studies. 
 
Table 5 - Aromatic 1H NMR chemical shifts of 35 
Chemical shift (ppm) Splitting pattern J-coupling (Hz) 
6.9 Doublet 8.93 
7.0 Doublet of doublets 8.93, 3.21 
7.3 Doublet 3.21 
 
Figure 19 shows a clean sample of 37, with two aliphatic peaks and two aromatic 
peaks. The aliphatic peaks show a triplet and a quartet, indicating the removal of 
the carbonyl was successful. In the aromatic region, there are two peaks with the J-
couplings shown in Table 6. 
 
Table 6 - Aromatic 1H NMR chemical shifts of 37 
Chemical shift (ppm) Splitting pattern J-coupling (Hz) 
6.7 Doublet of doublets 8.7, 3.2 
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3.6 Synthesis of 2-(4-fluoro-2,5-dimethoxy-phenyl)ethanamine (2C-F, 44) 
 
Scheme 18 - Synthetic scheme of 2C-F (44); a) nitromethane, ammonium acetate, 
AcOH, reflux, 3 h, 47 %; b) LAH, anhydrous THF, RT, 3 h, 93 % 
 
For the synthesis of 44 (Scheme 18), the Reiche formylation was utilised as a one 
pot synthesis to add an aldehyde group, by using stannic chloride as a Lewis base 
in a Friedel-Craft’s style alkylation reaction (mechanism shown in Scheme 19). This 
binds to a chlorine from dichloromethyl methyl ether to form the intermediate 1-
[chloro(methoxy)methyl]-4-fluoro-2,5-dimethoxybenzene. Performing an acid base 
work up removed the methoxy group as MeOH and the chlorine ion as HCl, as well 
as removing the catalyst in the first acidic wash, to obtain a crude solid of 4-fluoro-
2,5-dimethoxybenzaldehyde. Following a recrystallization with EtOH, this was 
filtered and dried to give a white powder. Analysis of the 1H NMR spectrum, Figure 
20, showed the reaction was successful with an aldehyde, two aromatic and two 
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Figure 20 - 1H NMR (CDCl3, 400 MHz) spectrum of 42
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Scheme 19 - Reiche formylation mechanism with 1,4-dimethoxy-2-fluorobenzene and dichloromethyl methyl ether 
(R = 2,5-dimethoxy-4-fluorobenzene) 
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3.7 Synthesis of 2-(4-iodo-2,5-dimethoxy-phenyl)ethanamine (2C-I, 47) 
 
Scheme 20 - Synthetic route for 2C-I (47); a) phthalic anhydride, reflux, 6 h, 72 %; 
b) iodine monochloride, AcOH, 40 °C, 1 h, 76 %; c) hydrazine hydrate, IPA, reflux, 
12 h, 10 % 
 
This synthesis started with iodinating 2,5-dimethoxybenzaldehyde so it could follow 
a similar reaction scheme of 2C-F and 2C-C. This was due to one of the reagents 
Shulgin used being difficult to obtain (iodine monochloride, 1 M in AcOH). The 
method of Kaliyaperumal et al.145 was utilised to obtain 4-iodo-2,5-
dimethoxybenzaldehyde and followed this with the Henry reaction. However, this 
was unsuccessful. Baker et al.146 have discussed the effect of halogens in the m- 
and p-positions on a substituted phenyl ring undergoing substitution reactions. The 
polar effects that were observed from the halogen substituents originated from 
tautomeric (electron-releasing) and inductive (electron-attracting) mechanisms. 
With p-halogens in benzaldehyde, the inductive electron attraction gives a fractional 
positive charge in the benzene ring displacing the carbonyl side chain. Fluorine 
exhibited an electron releasing effect meaning it must have a large mesomeric effect 
to overcome and reverse the polarisation of the inductive effect, allowing substitution 
reactions to occur. Whereas the other halogens exhibited an electron-attracting 
effect decreasing in the order I > Br > Cl, making it difficult for substitution of the 
carbonyl group to occur. Therefore, alternative routes to synthesise 47 were 
investigated. The synthetic route found to synthesise 47 was to protect 2,5-
dimethoxyphenethylamine with phthalic anhydride, iodinate and then deprotect the 
phthalimide. 
 
Proceeding with the protection route (Scheme 20), Shulgin performed this on a 12 
g scale due to the final step (phthalimide deprotection) having a low yield (10%). 
The 1H NMR spectrum of 47 (Figure 21) in the aromatic area shows two peaks with 
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integration values of one each; the aliphatic region has the two methoxy peaks as 
well as the two methylene peaks (H2O peak at 4.91 ppm from CD3OD, Table 7). 
 









8 2.94 triplet 7.33 
7 3.14 triplet 7.33 
11 3.81 singlet  
13 3.82 singlet  
3 6.86 singlet  
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Figure 21 - 1H NMR (400 MHz, CD3OD) spectrum of 47.HCl
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3.8 Synthesis of 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N, 48) 
 
Scheme 21 – Synthetic scheme of 2C-N (48) 
 
Synthesizing this compound was performed by a nitro addition using nitric acid (16 
M) with 2,5-dimethoxyphenethylamine, Scheme 21, with the mechanism shown in 
Scheme 22. Direct nitration was successful in the presence of AcOH in which the 
free base crystallised. Upon 1H NMR, Figure 22, no further purification was required 
and was not converted to the hydrochloride salt due to the ease of use. 
 
 
Scheme 22 - Reaction mechanism for the nitro addition of 48 
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Figure 22 – 1H NMR (400 MHz, CDCl3) of 48.HCl 
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3.9 Synthesis of N-methoxybenzylphenethylamines (NBOMe’s, 49-55) 
 
Scheme 23 - Reaction scheme for the synthesis of NBOMe compounds (X = F, Cl, 
Br, I, Me, Et, NO2) 
 
The approach of Hansen et al.37 for NBOMe synthesis (Scheme 23) involved 
forming an imine between the free bases of the hydrochloride and an aldehyde (2-
methoxybenzaldehyde or nicotinaldehyde), followed by reduction with NaBH4 
(Scheme 24). Repeating this method found that yields obtained compared to 
Hansen’s did not match, for instance with 25C-NBOMe, a 25 % yield was obtained 
compared to the literature value of 86 %. Whilst performing the column 
chromatography step, the MeOH concentration in the eluent could increase due to 
the impurities running off the column quickly as well as decreasing the time for the 
product to come off. Once the product peak started eluting, a ninhyrdrin solution 
was used to spot test as it turned the peak a deep purple indicating a secondary 
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Scheme 24 - Reaction mechanism of a reductive alkylation (RNH2 = 
phenethylamine) 
 
The approach of Hansen et al.142 used to suspend the phenethylamine 
hydrochloride (1 mmol) in EtOH (10 mL) and TEA (1 mmol eq.) with stirring for 5-10 
min. After forming the free base, aldehyde (1.1 mmol eq.) was added and left to stir 
for 0.5 – 120 hr and the reaction was monitored via TLC (same as FCC eluent). 
Sodium borohydride (2 mmol) was added slowly and stirred for 1 hr and then 
concentrated in vacuo. The amber oil was partitioned between DCM and water with 
the organic layer being extracted, and the aqueous layer extracted further with DCM, 
dried with MgSO4 and concentrated in vacuo. An amber oil was purified via column 
chromatography (DCM-MeOH-NH3, 98:2:0.04 v/v) with the desired product being on 
the baseline, which was showed by staining the plate with a ninhydrin solution. After 
concentrating, the purified free-base was dissolved in EtOH (2 mL) followed by 
EtOH.HCl (1 M, 2 mL) and finally diluting with Et2O (50 mL) until crystals formed. 
The crystals was filtered and dried to obtain pure powders. 
 
When assigning the peaks (Figure 23, Table 8), comparison of 54 made it clear 
which peaks belonged to each group as the methoxy and methylene groups are 
both singlets and the aromatic protons are either doublets or triplets. This is 
consistent with all of the phenethylamine’s and their corresponding NBOMe’s. 
However, the fluorine derivatives differentiate from the rest of the halogenated 
spectra as the aromatic regions of both show doublets instead of singlets for atoms 
3 and 6. 19Fluorine has a spin-½ and is 100 % abundant allowing for proton-fluorine 
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coupling to occur. Thus, the multiplicity of some peaks increased (coupling constant 
J=12 Hz). 
 
Distinguishing between NBOMe derivatives is possible in street samples as fluorine 
exhibits doublets with hydrogens 3 and 6, whereas increasing the mass of the 
remaining halogens increases the distance (ppm) between hydrogens 3 and 6. 25C-
NBOMe has a difference of 6 ppm, 25B-NBOMe 19 ppm and 25I-NBOMe 47 ppm. 
However, a more robust method was utilised to distinguish between NBOMe 
derivatives by using GC-MS (page 52). 
 
All NBOMe derivatives formulated corresponded with the spectral data reported by 
Hansen et al.142 
 









8 3.02 Triplet 8.24 
7 3.22 Triplet 7.33 
18 3.78 Singlet  
20 3.82 Singlet  
23 3.89 Singlet  
10 4.24 Singlet  





13 7.09 Doublet 8.24 
6 7.34 Singlet  
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Figure 23 - 1H NMR (400 MHz, CD3OD) spectrum of 54.HCl
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3.10 Synthesis of N-pyridyls (NPyr’s, 56-62) 
Following the method of reductive amination outlined by Hansen et al.37 it was 
possible to synthesise hyperpolarisable molecules (Scheme 25). The aldehyde 
being used must contain a pyridine moiety and not have any substituents ortho to 
the nitrogen (due to steric hindrance preventing binding to the catalyst used for 
polarisation transfer). The first synthesis attempt used 4-pyridinecarboxaldehyde as 
this fits the polarising criteria, but the reaction was unsuccessful; TLCs taken during 
the imine formation step showed no indication of product formation. An alternative 
route looked at nicotinaldehyde, as again this would fit the criteria for SABRE 
derived polarisation. The synthesis used 28 as a starting reagent and was 
successful, affording 56 in 3 % yield. When looking at the properties of these 
compounds and their ability to polarise, it became possible that PET imaging 
compounds could be replaced. Seven isomers were synthesised to see if the 
molecular size and electronics of these compounds would alter their ability to 
polarise. To obtain the hydrochloride salt, twice the amount of ethanolic HCl was 
used due to there being two nitrogen regions. 
 
Scheme 25 - Reaction scheme for the synthesis of NPyr compounds (X = F, Cl, Br, 
I, Me, Et, NO2) 
 
Upon inspection of the data for this series of compounds, a lot of similarities were 
observed. This includes when running the 1H NMR for the free base of these 
compounds. One difference that was observed with 61 between the free-base and 
the HCl salt was the ethylene side chain. As seen in Figure 24 and Table 9, two 
triplets (peaks 7 and 8) changed to a multiplet (Figure 25). The N-H peak is also 
observed (circa 4.66 ppm) within the free-base 1H NMR spectrum and this was 
consistent between all of the compounds formulated in this series.  
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Figure 24 - 1H NMR (CD3OD, 400 MHz) spectrum of 61.HCl
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Figure 25 - 1H NMR (CD3OD, 400 MHz) spectrum of 61
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8 3.07 Triplet 7.33 
7 3.35 Triplet 8.24 
18 3.81 Singlet  
20 3.82 Singlet  
10 4.47 Singlet  
3 6.93 Singlet  





12 8.54 Doublet 8.24 
14 8.84 Doublet 4.58 
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3.11 Synthesis of N-fluoropyridyl derivatives (NPF’s, 63-69) 
Following the reductive amination reported by Hansen et al.37, this series of 
compounds used 5-fluoronicotinaldehyde as the starting reagent (Scheme 26). 
Again, it possesses a polarisable tether group (pyridyl) and allows for 19F NMR 
SABRE to be employed. Olaru et al.131 discuss the scope of fluorinated containing 
ligands in medical applications as contrasting agents for MRI by increasing their 
signal intensity using SABRE. The advantage of these fluorine-containing 
compounds is that there is no fluorine present in biological tissue, so there is no 
background signals when performing MRI. Their MRI results showed the increase 
in intensity after being polarised to be 75-fold, which shows the potential in this 
technique to be looked at in clinical investigations and molecular imaging. Therefore, 
this range of compounds were synthesised as they could have great potential to be 
used in molecular imaging. 
 
Scheme 26 - Reaction scheme for the synthesis of NPF compounds (X = F, Cl, Br, 
I, Me, Et, NO2). 
 
The range of NPF compounds exhibited the same splitting patterns in both 1H and 
13C NMR spectra. When looking at the aromatic region of 25I-NPF (Figure 26, Table 
10), the protons on the pyridyl show a doublet (3JHH = 9 Hz) and two singlets. 
Hydrogen 14 experiences the effect of deshielding from the adjacent nitrogen. 
The carbon NMR of 68 (Figure 27, Table 11) show five J-coupling constants which 
is consistent with 13C-19F coupling values and six singlets (Figure 28). The shift 
observed from C5 (85.1 ppm) is constant throughout the iodinated compounds due 
to the shielding effect moving it further upfield. By increasing the electronegativity of 
C5, this shifts it further downfield.   
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Figure 26 - 1H NMR (CD3OD, 400 MHz) spectrum of 68.HCl 
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8 3.08 Triplet 7.33 
7 3.36 Triplet 8.24 
18 3.82 Singlet  
20 3.82 Singlet  
10 4.49 Singlet  
3 6.94 Singlet  
6 7.35 Singlet  
14 8.41 Doublet 8.59 
12 8.87 Singlet  
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Figure 27 - 13C NMR (CD3OD, 101 MHz) spectrum of 68.HCl 
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7 28.9 Singlet - 
10 48.5 Singlet - 
8 48.8 Singlet - 
20 56.8 Singlet - 
18 57.7 Singlet - 
5 85.1 Singlet - 
3 115.1 Singlet - 
6 123.2 Singlet - 
2 126.9 Singlet - 
12 131.9 Doublet 19.3 
11 133.2 Doublet 5.4 
14 137.2 Doublet 29.7 
16 145.0 Doublet 4.1 
4 153.7 Singlet - 
1 154.5 Singlet - 




142 | P a g e  
 
 
Figure 28 - 13C NMR (CD3OD, 101 MHz) spectrum of the aromatic region of 68.HCl
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3.12 Synthesis of N-methoxypyridyls (NPOMe’s, 70-76) 
The final series of compounds synthesised using Hansen’s methodology was the 
NPOMe’s (Scheme 27). This was our primary focus due to their resemblance to 
NBOMe’s, which would allow comparison to the PET imaging counterparts. 
 
Scheme 27 - Reaction scheme for the synthesis of NPOMe compounds (X = F, Cl, 
Br, I, Me, Et, NO2) 
 
The 1H NMR of 75 shows three aromatic peaks and five aliphatic peaks as shown 
in Figure 29 (Table 12). This was consistent throughout the NPOMe derivatives 
apart from 25F-NPOMe, where hydrogens six and three appear as doublets due to 
the fluorine coupling.   
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Figure 29 - 1H NMR (CD3OD, 400 MHz) spectrum of 75.HCl 
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8 3.09 Triplet 6.4 
7 3.36 Triplet 7.6 
18 3.82 Singlet  
20 3.83 Singlet  
23 4.28 Singlet  
10 4.44 Singlet  
3 6.96 Singlet  
6 7.35 Singlet  
13 7.78 Doublet 6.9 
14 8.85 Doublet 6.9 
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3.13 GC-MS 
Comparing 47 and 54, the mass spectra are very different as the fragments seen in 
47 are not all seen in 54 (peak at m/z=207 is background noise). This can be seen 
in the fragmentation pathways in Figure 30 and Figure 31. The GC-MS mass spectra 
of 47 are shown in Figure 32a and was compared to the spectrum of 54 (c - GC-MS 
chromatogram from Cayman Chemicals). 
 




147 | P a g e  
 
 
Figure 31 – GC-MS fragmentation pathway of 54
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Figure 33 – Chromatogram of 25F-NBOMe (53, D) with subsequent starting 
materials 
 
When looking at retention times between each reaction step, observing purity of the 
final NBOMe is possible as each compound has a different retention time. For 
example with 25F-NBOMe, there were three subsequent reactions with the retention 
times (Figure 33) being 5.368 min (42, A), 7.065 min (43, B), 5.802 min (44, C) and 
8.692 min (53, D).  
 
When looking at the derivatives of NBOMe’s, the same fragmentation pattern 
occurs. Therefore, there are two ways to differentiate between them being retention 
times and isotopic ratios. The size of the halogen affects the retention times as the 
smallest compound being the 25F-NBOMe elutes at 8.692 min and progressively 
increases to 9.225 min (25C), 9.506 min (25B) and 9.851 min (25I). When looking 
at isotopic ratios and abundancy (%), 19fluorine and 127iodine is 100 %, 35chlorine 75 
% and 37chlorine is 25 %, 79bromine 50 % and 81bromine 50 %. The mass spectra 
of compounds possessing chlorine and bromine will therefore be different due to 
M+2 peaks being observed in a 3:1 or 1:1 ratio respectively. The fluorine and iodine 
can be differentiated by the m/z, as some peaks will have a difference of m/z=100 
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3.13.1 NBOMe calibration analysis 
Eight analogues of NBOMe’s were all injected into the GC-MS and ran individually 
(1 mg mL-1) to determine retention times (Rt) before being run as a mixture. Table 
13 shows the retention times of the individual runs.  
 




A 25F 8.629 
B 25H 8.710 
C 25D 8.862 
D 25E 9.052 
E 25C 9.369 
F 25B 9.818 
G 25I 10.426 
H 25N 10.614 
 
As there are no co-eluting peaks, method validation was performed using SIM mode 
with eicosane as an internal standard (Rt – 7.234 min). SIM mode was used as the 
base peak for all the NBOMe’s was m/z 121. By using this method, it reduces the 
concentration required to obtain sharp peaks. Figure 34 displays a chromatogram 
of the NBOMe mixture at a concentration of 20 µg mL-1. Street samples typically 
ranging from 300 µg – 1 mg. Therefore, by minimising the concentration of the 
analyte, an accurate concentration can be generated from a street sample. But as 
street samples are not necessarily 100% pure, and the dangers which can arise 
from consumption, a lower limit of detection (LOD) and limit of quantification (LOQ) 
would increase the accuracy of the drug concentration within the street sample.  
 
 
151 | P a g e  
 
 





152 | P a g e  
 
The developed method was validated individually for a mixture of the NBOMe 
derivatives. All correlation coefficients are above an acceptable level (>0.99) for the 
compounds, with limits of detection (LOD) and limits of quantification (LOQ) values 
shown in Table 14. LOD values range between 6.20 – 10.75 μg mL-1 and LOQ 
values ranging from 18.77 – 32.57 μg mL-1. All, but 25H-NBOMe, relative standard 
deviation percentages fall below an acceptable 4% and can also be seen in Table 
14. 
 
What these results enable is the ability to accurately measure the concentration of 
NBOMe’s within a mixture. At present, this is only applicable for a powdered sample. 
However, most cases of NBOMe’s are found within a blotter. Further work details 
















Precision (%RSD) n=6 
10 µg mL-1 15 µg mL-1 20 µg mL-1 25 µg mL-1 30 µg mL-1 
25F 8.63 0.995 7.36 22.29 3.30 0.42 1.07 1.14 1.29 
25H 8.71 0.995 6.20 18.77 3.55 7.30 4.62 6.48 7.66 
25D 8.86 0.995 6.81 20.63 3.39 1.29 1.75 2.30 2.97 
25E 9.05 0.995 7.69 23.32 0.64 1.18 1.60 2.10 2.73 
25C 9.37 0.993 7.68 23.27 0.69 1.24 1.70 2.26 2.97 
25B 9.82 0.995 6.67 20.21 0.54 1.08 1.53 2.05 2.70 
25I 10.43 0.994 8.90 26.97 0.36 0.76 1.13 1.55 2.09 
25N 10.61 0.992 10.75 32.57 0.13 0.41 0.72 1.09 1.52 
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3.13.2 Street sample analysis 
25C, 25B and 25I are the most commonly found substances from the range of 
NBOMe’s in blotters, so street samples were prepared (as individuals) and tests 
followed using the blotter dry and after extraction.  
 
Using the dried blotters, presumptive colour testing (Marquis and Liebermann’s) and 
ATR-FTIR analysis provided limited results. During the colour test it was found that 
due to the high acidity of the testing solutions, this interfered with the colour output 
(Table 15). The bee patterned blotter had a yellow and black print (Figure 35) which 
leached into the well, and in some cases turned the solution brown after being left for 
more than 15 mins. With ATR-FTIR analysis, a spectrum was recorded for both types 
of impregnated blotters as well as a blotter with no impregnation as a control. An 
example of ATR-FTIR analysis is shown in Figure 36 with spectrums of the 
unadulterated blotting paper (A), 25C-NBOMe (B) and the blotter adulterated with 
25C-NBOMe (C). When compared, no change could be seen due to the sensitivity 
with this technique when using microgram scale. Therefore, qualitative analysis is 
possible using the blotters but the variant is what kind of print is on the paper. As the 
patterned paper used was white, black and yellow, the correct colours upon the 
addition of the presumptive testing solution was only visible on the white area with the 




Figure 35 – Blotting paper used for street sample analysis  
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Figure 36 – ATR-FTIR spectra of an unadulterated blotter (A), 25C-NBOMe (B) and a 
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Table 15 - Presumptive colour test of impregnated blotters 
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After extraction, presumptive colour testing (Marquis and Liebermann’s) and GC-MS 
analysis provided both qualitative and quantitative results. With the presumptive colour 
testing results (Table 16), this showed the correct colour changes with each drug; the 
colour output was transparent but due to the lower concentrations this was expected. 
Table 16 - Presumptive colour test output after extraction 
















Control Peach Peach Dark green Yellow 
Blotter 
(plain) 
Faint yellow Clear Clear Clear 
Blotter 
(bee) 
Faint peach Clear Clear Clear 
25B-
NBOMe 














Control Green Green Brown Brown/yellow 
Blotter 
(plain) 
Green Green Brown Brown 
Blotter 
(bee) 
Green Green Brown Brown/yellow 
 
Upon extraction and dilution to the suitable concentration range, which fit within the 
calibration plot, GC-MS analysis provided both qualitative and quantitative results. A 
separate run of 300 µg mL-1 25B-NBOMe, 500 µg mL-1 25C-NBOMe and 800 µg mL-1 
25I-NBOMe with eicosane (250 µg mL-1) was run against the extracted solutions to 
compare the extraction method performance against the output from the calibration 
plot (Table 17). The dilution stocks from each blotter set was concentrated in vacuo 
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9.359 80 10.09 33 15.67 
Blotter 
(bee) 




9.808 49 7.38 19 7.29 
Blotter 
(bee) 




10.406 81 3.98 19 3.55 
Blotter 
(bee) 
10.408 63 34.64 10 2.81 
 
Extraction from the plain blotting paper was higher in all three drugs for both the diluted 
and concentrated. This suggests there is a possibility of the drug interacting with the 
ink or the kind of paper used, as the plain blotting paper looked more porous which 
could lead to an increase in extraction rates. Examples are shown in Figure 37 of the 
chromatograms of 25C-NBOMe blotters. The plain patterned blotter (A) in the 
chromatogram shown extracted 410 µg (82 %), whereas the bee patterned blotter (B) 
extracted 348 µg (70 %)  
 
Extension of the validation of NBOMe’s has enabled an accurate and precise method 
to analyse NBOMe’s within a street sample. After performing analytical techniques of 
the raw samples, this concluded that it is not possible to determine what is present 
within a blotter. Therefore, samples which have been spiked with an NBOMe derivative 
must be extracted, with MeOH, before analysis. The described post extraction 
techniques can be used both qualitative and quantitatively.   
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Figure 37 – GC-MS chromatograms of the extraction of 25C-NBOMe from a plain 
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4 Chapter 4 - Hyperpolarisation 
4.1 Introduction 
Hyperpolarisation techniques have been increasingly useful to overcome the 
sensitivity issues involved with NMR and MRI. Methods involving hyperpolarized 
magnetic resonance spectroscopy (MRS) have been successful for 1H,98 13C,147 15N148 
and 19F149 detection. The current techniques include dynamic nuclear polarisation 
(DNP),150 spin exchange optical pumping (SEOP)151 and parahydrogen-induced 
polarisation (PHIP).92 An example of an advance in hyperpolarised MR imaging utilises 
SEOP to create hyperpolarised xenon and helium gas to image lung space to visualise 
lung diseases such as cystic fibrosis.152 Using this technique, all 23 branches of the 
lungs can be imaged which contrasts with computerised tomography, which can image 
the first six only. A further example utilises DNP to obtain images of prostate cancer. 
This approach uses 13C-labelled pyruvate,153 which is metabolised through the Kreb’s 
cycle to acetyl CoA. Hyperpolarised pyruvate is used as a biomarker to acquire 13C 
images of the colon in order to provide images of this tissue to better inform diagnosis.  
The focus of this chapter is the employment of the non-hydrogenative form of PHIP, 
SABRE.102 SABRE does not require the molecule of interest to be directly 
hydrogenated to facilitate polarisation transfer, unlike PHIP that does. The source of 
polarisation in SABRE is parahydrogen, a spin isomer of di-hydrogen. Parahydrogen 
is a nuclear singlet and has a total spin of zero and so is not visible in an NMR 
experiment. However, by breaking the symmetry of parahydrogen, such as at a metal 
centre (typically iridium) through the formation of hydrides, the polarised state 
becomes unlocked and can be transferred to other spin-1/2 nuclei through J-coupling 
that has been established between parahydrogen-derived hydrides and the spin-1/2 
nuclei of ligands bound trans to them. Both the parahydrogen-derived hydrides and 
ligands freely exchange at the metal centre, enabling polarisation to be built up in the 
bulk. This creates a pool of hyperpolarised free-ligand, which can be interrogated 
using radio-frequency pulses to obtain the representative, significantly enhanced, 
NMR spectrum.  
 
This powerful analysis technique can be used in forensic applications. In the last two 
years, derivatives of fentanyl99 (77) and benzylpiperazines100 (81) (Figure 38 and 
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Figure 39 respectively), have both been polarised. It is noteworthy that these fentanyl 
and BZP derivatives have been modified to include a pyridyl function, in order to create 
a ligation point to the metal centre. This interaction is needed to facilitate polarisation 
transfer from parahydrogen derived hydrides to the derivatives highlighted via the 
established J-coupling. 
 
Current methods of analysis of fentanyl analogues include Raman spectroscopy, 
immunoassays, LC-MS/MS and low-field NMR in conjunction with high-field NMR. 
Raman spectroscopy has been utilized in combination with density-functional theory 
(DFT) towards detection of trace samples. Surface-enhanced Raman spectroscopy 
proved to give an enhancement factor of ≥1.6×105, which was endowed by proximity 
to silver or gold nanoparticles.154 Immunoassay has also been investigated as a 
technique for the detection of fentalogues, but none of the ELISA (Enzyme-Linked 
ImmunoSorbent Assay) kits evaluated proved to have sufficient cross-reactivity 
towards the N-acyl and piperidine-modified fentalogues studied.155 LC-MS/MS has 
been utilized to detect 24 fentanyl derivatives and metabolites in whole blood in under 
14 min screening time with a LOD of 0.05 ng mL-1 and lower limit of quantification 
(LLOQ) of 0.1 ng mL-1.156 Developments in fentanyl analysis has been shown by 
Elbardisy et al.157 where an electrochemical approach was taken. A combination of 
LC-MS with a dual-diode array and electrochemical (amperometric) detector achieved 
simultaneous detection of heroin, fentanyl and 10 fentalogues. However, with a LOD 
of 0.41 µg mL-1 and a LOQ of 1.39 µg mL-1, this technique is not as sensitive as that 
shown by Strayer et al.156  
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Figure 38 – Fentanyl (77) and the pyridyl-fentanyl analogues prepared by Robertson 
et al.99 for hyperpolarisation studies; N-phenyl-N-(1-(2-(pyridin-4-yl)ethyl)piperidin-4-




Gilbert et al.158 highlighted that GC-MS and presumptive testing can be employed for 
detecting, and discriminating between different fentalogues. GC-MS (SIM mode) was 
used to differentiate 18 fentalogues, five controlled substances and four adulterants. 
The sensitivity of this technique yielded a LOD of 0.034 µg mL-1 and LOQ of 0.01 µg 
mL-1. Along with this, presumptive testing with Scott’s, Marquis and Eosin Y provided 
rapid results (5 mins) to determine whether fentanyl was present within a sample.  
 
Furthermore, low-field (62 MHz) NMR spectroscopy has been used to differentiate 65 
fentalogues in conjunction with quantum mechanical spin system analysis of spectra 
acquired at a frequency of 600 MHz to produce comparison spectra. Low-field NMR 
was selected in this instance due to the cost saving attributes it possesses (smaller 
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footprint, no need for cryogens, cheaper instrument cost) over high-field 
instrumentation.159 
 
Robertson et al.99 sought to employ a method of detection, due to the low-threshold 
for overdose, of fentalogues within a heroin matrix (97 % w/w). SABRE was chosen 
as it would be able to detect a fentalogue within a single scan, thus saving instrument 
time whilst significantly increasing the signal intensity observed. Enhancements of 50-
fold, 168-fold and 38-fold were reported for the ortho-pyridyl protons of 78, 79 and 80 
respectively. 78 was selected to be tested within a matrix of heroin (ratio 97:3; 
heroin:78), with the ortho- hydrogen being enhanced by 47-fold initially, although this 
subsequently fell to 24-fold in further polarisation experiments. 
 
Figure 39 - Benzylpiperazine (81) and the pyridyl-BZP analogues (PMP) prepared by 
Tennant et al.100 for hyperpolarisation studies; 1-(2-pyridylmethyl)piperazine (82, 2-
PMP), 1-(3-pyridylmethyl)piperazine (83, 3-PMP), 1-(4-pyridylmethyl)piperazine 
(84, 4-PMP) 
 
 Tennant et al.100 reported that the pyridyl-BZP analogues (Figure 39) do not all have 
the same enhancement values. Enhancements for the signal of the ortho-pyridyl 
protons differ in that 2-PMP (82) yields a negligible enhancement, 3-PMP (83) an 
enhancement of eightfold and 4-PMP (84) an enhancement of 313-fold. This highlights 
the problems faced with pyridyl isomers binding with the catalyst due to steric 
hindrance. For 82-84, steric hindrance increases in the order 82>83>84. In the case 
of 82, steric hindrance was reported to completely hinder binding to the metal centre, 
thus preventing polarisation transfer. Again, hindrance problems are evident for 83 as 
reflected in the low enhancement, however, optimisation of the magnetic field utilised 
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for polarisation transfer could improve these further.100 Similar to the fentalogues, this 
study focussed on the para-isomer of PMP including the polarisation on the 
hydrochloride salt (4-PMP.3HCl). Traditionally, SABRE requires the analyte to be a 
free-base so the nitrogen can ligate to the metal centre. Therefore, attempts to polarise 
the salt using the same methodology did not result in polarisation transfer.100 
Overcoming this issue by the addition of triethylamine (TEA) in-situ results in 
successful polarisation, with the addition of 3 eq. of TEA producing an enhancement 
of 300-fold for the ortho-pyridyl protons. 
 
When looking at the biological aspects of SABRE, what has to be considered is 
forming a heterogeneous catalyst as well as the safe removal of the spent catalyst. 
Such work has been investigated by Goodson et al. who took [Ir(IMes)(COD)][PF6] 
(IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene, COD = cyclooctadiene) and 
tethered it to a commercially available polymer microbead functionalised with 4-
dimethylaminopyridine (Figure 40). 160, 161 
 
Figure 40 - Structure of heterogeneously solid supported SABRE catalyst synthesised 
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This complex was used to polarise pyridine in CD3OD, resulting in three signals being 
found with the enhancements ranging from threefold to fivefold (ortho-hydrogen gave 
the strongest enhancement). It was also found that extraction of the supernatant liquid 
produced no SABRE-based polarisation transfer. Thus, the catalyst remained firmly 
bound to the support during polarisation transfer, which is important for the SABRE 
approach towards the delivery of hyperpolarisable bolus, as the normally used catalyst 
[Ir(IMes)(COD)Cl] has been shown to be toxic.97 
Methanol is the typical solvent used in polarisation, but as methanol is not biologically 
compatible, alternatives have been investigated. The use of ethanol/water mixtures 
have been used to good effect with the polarisation of nicotinamide (amide of vitamin 
B3). Nicotinamide polarised by [Ir(IMes)(COD)Cl] in a ratio of 16:1 yielded a 70-fold 
enhancement for the proton α to both the ring nitrogen and the amide functional 
group.162 By using a 50:50 mixture of D2O:d6-ethanol an enhancement of 105-fold was 
achieved. Nicotinamide can be polarised in neat water, however, the preparation has 
to be altered. This can be achieved by activating the SABRE catalyst and nicotinamide 
in neat ethanol, followed by removal of the solvent and reconstituting in D2O. Water 
soluble catalysts have been prepared and tested,96 with 
[Ir(IMes)(MeCN)(pr)(H)2(mtppms)BF4] having an enhancement of 71-fold in CD3OD, 
similar to the enhancement obtained in a 30% mixture of ethanol-water mixture. 
Therefore, when looking at polarising the compounds in this study, steps have been 
made for future biological uses.  
 
Due to the increase in signal-to-noise ratios over the years, SABRE as a technique 
has been vastly improved. The analyte can now be detected at far lower 
concentrations than NMR. However, these concentrations will have to be lower if they 
are to be used safely within the body. NBOMe’s become dangerous exceeding a dose 
of 1 mg, whereas the current masses used contain 3 – 5 mg. How these drugs will 
react in the body is still unknown but this is a step in the right direction.  
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4.2 Results and discussion 
The catalyst used throughout this study was [Ir(COD)(IMes)Cl] (85, Figure 41) and all 
experiments were performed at 4 molar equivalents constituted in CD3OD. This was 
due to the investigation focussing on determining if SABRE polarisation transfer to the 
NBOMe ligands was possible, following interrogation by NMR methods.  
 
Figure 41 - Structure of the iridium catalyst used in hyperpolarisation experiments. 
 
The catalyst chosen is highlighted by Mewis94 as being the first carbene complex to 
be used in conjunction with SABRE and was first utilised in 2011.95 It focused on the 
use of IMes to form the complex (85), which following activation by hydrogen in the 
presence of pyridine (py) gave [Ir(IMes)(H)2(py)3]Cl (py = pyridine). Thus, it was 
structurally analogous to the mono-phosphine complexes reported previously, as both 
utilise electron rich ligands.163 Comparison of [Ir(IMes)(H)2(py)3]Cl (86) and 
[Ir(PCy3)(H)2(py)3]Cl (87) (Figure 42) as SABRE catalysts led to the observation that 
the former enhanced the meta 1H signal of pyridine in CD3OD by 266-fold 
(Polarisation, P = 0.4%), whilst the latter only achieved 18-fold (P = 0.03%). Therefore, 
the inclusion of the more electron-donating NHC ligand in the polarisation transfer 
catalyst led to a significant improvement in the observed enhancement.94 
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Figure 42 - Chemical structures of [Ir(IMes)(H)2(py)3]Cl (86) and [Ir(PCy3)(H)2(py)3]Cl 
(87) as studied by Cowley et al.95 to ascertain the effect of the carbine / phosphine 
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4.2.1 Hyperpolarisation of NPyr ligands using [Ir(IMes)(COD)Cl] 
Hyperpolarisation studies begun with evaluating the ability of catalyst 85 to form 
efficient SABRE polarisation transfer catalysts with compounds 56 – 62. Table 18 
shows the enhancement of the ortho-pyridyl 1H nuclei after polarisation transfer in 
earth’s magnetic field (0.5 G, 0.5x10-4 T). The enhancements from highest to lowest 
for 49 – 55 were found to be Cl > NO2 > Br > Et > F > I > Me. 
 
 
Table 18 - Enhancement values of NPyr compounds. 
R NPyr 
1H Enhancement of o-Hα in 
earth’s magnetic field 
Br 56 108 
Cl 57 127 
Me 58 25 
Et 59 98 
F 60 55 
I 61 48 
NO2 62 113 
 
56 was examined first with an enhancement being visible, indicating the formation of 
[Ir(H2)(IMes)(56)3]Cl when examined under SABRE. Evidence for the formation of 
[Ir(H2)(IMes)(56)3]Cl was obtained in that a single strong hydride signal was observed 
at −22.8 ppm, which suggests the complex is symmetrical in that the hydrides are 
chemically equivalent. Similar hydride shifts have been identified for analogous pyridyl 
complexes,164 fentalogues99 and BZP100 complexes, all of which possessed 
chemically-equivalent hydride signals at ca. -23 ppm. Figure 43 shows the comparison 
of the thermal spectrum of 56 with the hyperpolarised spectra. When comparing 56 
with the other halogenated NPyr’s (57, 60, 61), there is a decrease in enhancement 
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molecular size of these compounds making it difficult for them to bind to the catalyst. 
High field NMR shows that three ligands bind to the iridium centre, therefore increasing 
the ligand size could implicate equatorial binding. However, if this was the case then 
58 would have a larger enhancement than 61. 
 
As shown in Figure 43, the thermal spectrum is shown at x4 magnification relative to 
the hyperpolarised spectrum. The hyperpolarised spectrum shows an enhancement 
of 108-fold (the right hand side of Figure 43 displays the hydride peaks). As there is 
only one hydride peak, this would indicate that there is symmetrical binding to the 
catalyst. However, due to the activation process involved with the SABRE technique, 
the first shake with parahydrogen shows three peaks in the hydride region. The peaks 
shown at -12.5 ppm and -16.5 ppm is due to the hydrogenation of one of the double 
bonds of COD to octene. Subsequent spectra do not possesses these peaks as the 
COD moiety has been completely hydrogenated to octane. The hydrogenation of the 
COD ligand is a necessary step in the production of [Ir(H2)(IMes)(56)3]Cl from 
[Ir(IMes)(COD)Cl], the former being the fully activated form of the polarisation transfer 
catalyst. 
 
Figure 43 – 1H NMR spectra of 56 in the presence of [Ir(IMes)(COD)Cl and 
parahydrogen at thermal equilibrium (bottom), after the first polarisation transfer at 
earth’s magnetic field (middle) and subsequent polarisation transfer at earth’s 
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At the start of the activation process (process shown in Scheme 28), the chloride in 85 
can be easily displaced by 56 to give [Ir(IMes)(COD)(56)] (both complexes are square 
planar). The oxidative addition of parahydrogen to the metal centre causes a change 
in oxidation state from +1 to +3 along with hydrogenating one of the double bonds of 
COD i.e. the complex [Ir(IMes)(CODH2)(H)2(56)2]+ could be postulated. COD would 
then be fully hydrogenated to cyclooctane enabling the fully formed version of the 
catalyst [Ir(IMes)(H)2(56)3]+. The signals are more deshielded for the hydrides when 
one of them is trans to an alkenic bond – this is the hydride at -12.5 ppm whereas the 
one at -16.5 ppm is most likely trans to NBOMe. This is why after the first shake, the 
peaks between 12 – 17 ppm are quickly replaced by the dominant symmetrical hydride 
at -22.8 ppm. 
 
Scheme 28 – Iridium catalyst sequence during the first shake of SABRE polarisation 
 
Upon the addition of hydrogen, the sample started to go colourless. The single hydride 
observed at -22.8 ppm indicates that symmetry is within the complex, similar chemical 
shifts have been reported for the hydride ligand for a range of different 
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4.2.2 Hyperpolarisation of NPF ligands using [Ir(IMes)(COD)Cl] 
The structure of the NPF’s allow for both 1H and 19F SABRE polarisation, both of which 
were performed in this study. The enhancement values are given below in Table 19 
(highest to lowest being F > Cl > NO2 > Me > Br, Et > I). Hyperpolarisation transfer 




Table 19 - Enhancement values of NPF compounds. 
R NPF 
1H Enhancement of o-Hα 
in earth’s magnetic field 
19F Enhancement of F 
on the pyridine ring in 
earth’s magnetic field 
Br 63 2 13 
Cl 64 37 - 
Me 65 4 - 
Et 66 2 - 
F 67 46 - 
I 68 - - 
NO2 69 23 - 
 
As evidenced from Table 19, the enhancements were all significantly lower compared 
to the NPyr’s. However, the marginal enhancements again provide evidence that these 
compounds can be polarised by SABRE. 67 gave the highest 1H NMR enhancement 
of 46-fold for the ortho-pyridyl Hα (Figure 44). Conversely, there was no enhancement 
observed for 68 after multiple purges. The difference in the atomic radii of F (67) and 
I (61) may result in the former having greater accessibility for the metal centre (due to 
reduced sterics), despite the halogen being located far from the pyridyl nitrogen. If the 
halogenated compounds are considered, then enhancement increases in the order F 
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seems to not correlate with this trend; it would be expected that this group would 
produce an enhancement of effectively zero.  
 
Figure 44 -1H NMR spectra of 67 in the presence of [Ir(IMes)(COD)Cl and 
parahydrogen at thermal equilibrium (bottom) and after polarisation transfer at earth’s 
magnetic field (top). 
 
Olaru et al. recently showed that the polarization transfer of four equivalents of 
voriconazole (91, Figure 45) using 85 in the presence of p-H2 in earth’s magnetic field 
led to the pyrimidine ring protons being enhanced only two-fold. Compared with the 
other ligands studied, 91 possesses the greatest steric bulk, and so this could be the 
main factor for the low enhancement obtained. When the ratio of 91/85 was increased 
to 20:1, SABRE enhancement of the pyrimidine ring protons was not detectable, due 
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Figure 45 – Voriconazole (91) which was SABRE hyperpolarised by Olaru et al.131 
 
Although steric bulk of the analyte molecules could be a cause for why enhancements 
are lower compared to those detailed in 4.2.1 there are a number of other factors 
including Shoolery’s rule,165 proton dilution, pKa, electron effects and human error.166 
When comparing the general shape of the NBOMe’s, these are linear which would 
indicate that there would be less stress binding to the iridium centre despite their 
general size. However, 91 has more of a triangular or wedge geometry, increasing the 
potential of steric clashing. Thus, a main factor as to why these enhancements are so 
low is due to the difference in molecular architectures compared to the NPyr 
compounds. Further studies could look at the relaxation times between all three sets 
of molecules to determine whether the fluoro- or methoxy-substituent is effecting the 
polarisation longevity of the ortho-hydrogens. Several groups have investigated the 
effect of T1 on the longevity of the hyperpolarised signal. For example, the fentalogues 
78-80 all possess pyridyl 1H T1 values of 2.1-3.5 s. In the space of 5-6 T1s, the spin-
lattice magnetisation is fully restored, thus meaning complete loss of 
hyperpolarisation. In the case of 78-80 this is ca. 18 s. Comparatively, the T1 of pyridyl 
protons are much longer (ca. 12 s). Larger molecules tend to have shorter T1 values 
due to increased molecular tumbling rates. This would most likely apply to the NPF 
compounds (63 - 69) investigated herein.  
 
Following the addition of p-H2, shaking for 10s and being placed in a spectrometer, a 
19F NMR spectrum was recorded of 70 (Figure 46). The 19F nuclei were enhanced by 
13-fold following polarisation transfer in earth’s magnetic field, based on integral 
differences between the hyperpolarised spectrum and the spectrum at thermal 
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equilibrium. The signal-to-noise (S/N) differential between the thermal and polarised 
spectrum were enhanced 6-fold (evaluated by dividing the mean signal value by the 
standard deviation of the background noise).  
 
It is beneficial to hyperpolarise the 19F nuclei of molecules because there are no 
natural molecules within the body that contain fluorine. This is not true of 1H, for which 
a large background signal is present in the body, meaning that large enhancements 
are required in order to successfully translate the technique to MRI, in order to collect 
MR images. In terms of 19F imaging, there will be no background noise, making the 
signal easier to see. 
 
 
Figure 46 – 19F NMR spectra of 56 in the presence of [Ir(IMes)(COD)Cl and 
parahydrogen at thermal equilibrium (bottom) and after polarisation transfer at earth’s 
magnetic field (top). 
 
Olaru et al.131 reported successful 19F polarized of the 19F nucleus on the pyrimidine 
ring. It possessed an enhancement of fivefold following polarisation transfer at earth’s 
magnetic field and was observed as an anti-phase signal. However, no polarization 
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was observed for the other two 19F nuclei, owing to insufficient J coupling to propagate 
polarization to these two nuclei. Despite the low enhancement observed, the T1 of the 
polarized 19F resonance is 5.15 s in a measurement field of 1.4 T. This is comparable 
to the T1 observed for a ratio of 20:1 91/85 at 11.74 T for the other substrates 
studied.131 The anti-phase signal observed indicates asymmetrical binding to 85, 
enforcing that steric hindrance would be a cause for the low enhancements. Compared 
to the symmetrical binding of 56, which provided a slightly higher enhancement, the 
rigidity of a larger compound could be the cause of greater steric hindrance. 
 
Olaru and co-workers also reported that although the results of the 19F 
hyperpolarization studies are very promising and exhibit enhancement values high 
enough to enable high-resolution images (with the exception of 91) to be recorded, 
they are two orders of magnitude lower than those obtained for 1H. This is a 
remarkable decrease considering the high sensitivity of 19F, which is very close to that 
of proton. In order to fully rationalize this difference, one must take into account the 
relaxation and exchange rates for the ligands analysed, as well as the dependence of 
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4.2.3 Hyperpolarisation of NPOMe ligands using [Ir(IMes)(COD)Cl]  
Finally, the NPOMe class of compounds were investigated to see if they could be 
hyperpolarised by SABRE. The lack of 19F nuclei in these compounds meant that the 
focus was on their respective 1H polarisations, with focus being on the pyridyl ring as 
this point of ligation meant that J-coupling was maximised for polarisation transfer. 
With their similarities to the NBOMe’s, it was expected that the NPOMe class would 
hyperpolarise similarly. The enhancement values for ligands 63-69 are given below in 
Table 20 (highest to lowest being Br > F > Et > NO2 > Cl > I > Me). 
 
Table 20 - Enhancement values of NPOMe compounds. 
R NPOMe 
1H Enhancement of o-Hα in 
earth’s magnetic field 
Br 70 192 
Cl 71 31 
Me 72 3 
Et 73 53 
F 74 161 
I 75 12 
NO2 76 38 
 
Figure 47 displays the 1H NMR spectra of 63, following polarisation transfer or at 
thermal equilibrium. Following polarisation transfer at earth’s magnetic field, the pyridyl 
ortho-protons were enhanced by 192-fold. This was the largest enhancement 
observed for all the compounds investigated. Furthermore, the value of enhancement 
is slightly higher than the fentanyl results obtained by Robertson et al. who reported 
an enhancement of 168-fold for the ortho-pyridyl protons of 79.99  
 
A single hydride peak is again observed at –23 ppm. During the first SABRE 
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only a single peak in subsequent spectra. Again, this is due to the COD being 
hydrogenated as was shown for the polarisation of 56. 
 
Figure 47 – 1H NMR spectra of 70 in the presence of [Ir(IMes)(COD)Cl and 
parahydrogen at thermal equilibrium (bottom), after the first polarisation transfer at 
earth’s magnetic field (middle) and subsequent polarisation transfer at earth’s 
magnetic field (top). 
 
As steric hindrance could be considered a common issue throughout the differing class 
of NBOMe derivatives, the A-values could be considered. As the A-values of these 
groups could be utilised to provide guidance relating to their steric properties. This is 
despite these values being associated with cyclohexane, and not phenyl rings. The 
order of these A-values (Table 21) generally coincide with the results presented 
herein, with the exception of iodine, indicating that steric hindrance within the phenyl 
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Table 21 - A-Values of substituents on cyclohexane (average values) 
Substituent A-Value (kcal mol-1) 
F 0.26167, 168 
Br 0.38167, 168 
I 0.46167, 168 
Cl 0.48167, 168 
NO2 1.09167, 168 
Me 1.70 
Et 1.75 
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4.3 Conclusion 
This chapter has detailed the evaluation of a range of NPyr’s, NPF’s and NPOMe’s to 
from complexes with [Ir(IMes)(COD)Cl] (85) and p-H2 to facilitate the successful 
polarisation transfer to both 1H and 19F nuclei. Positive 1H enhancements were found 
for all molecules (excluding 68) alongside the positive 19F enhancement for 63, 
indicating that these compounds can be hyperpolarised by SABRE. Furthermore, it 
indicates that these compounds could be used as potential MRI contrast agents, 
especially so for 63 due to the low / negligible 19F background of the human body.   
 
From the data, the trend that was observed at earth’s magnetic field was that, in 
general, NPyr’s > NPOMe’s > NPF’s in terms of enhancements (from the average 
calculated between the class). This trend, highlights that steric hindrance is a factor in 
terms of enhancement potential. Observing the general trends within each class, it is 
noted that Br > F > Cl > Nitro > Et > I > Me based on average enhancements of the 
three classes. Steric hindrance is a concern with respect to ligation, alongside the 
linear geometry of these compounds. Whilst there would be some rotation in the 
backbone of the compound, the bulkiness of the dimethoxy phenyl (including the R-
group) would come into effect. The A-values of these groups could be utilised to 
provide guidance relating to their steric properties. As previously discussed, they 
generally coincide with the enhancements values given within the three different 
classes.  
 
However, steric hindrance is not the only factor that contributes to enhancement 
potential. One of the factors could be due to the ligands pKa. There is no literature 
values for the ligands discussed, so predicted values were obtained. Throughout the 
three classes, the pKa values are between 8 and 9 whereas pyridine has a pKa of 5.23. 
This entails the Ir-N(ligand) bond length would be shorter than when pyridine is bound. 
Shorter bond lengths would suggest there would be an increase in steric clashing. 
However, as the estimated pKa’s are similar, there is clear differentiation between each 
series within the enhancement data. This highlights that the ligands’ pKa is an unlikely 
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Proton dilution is an effect where it is assumed that polarisation transfer is equal, and 
takes account of the number of protons that could be polarised. This is a suitable 
theory for the ligands mentioned as the environments differ between each class. The 
NPyr’s have four protons, NPF’s have three protons and one fluorine and the 
NPOMe’s have three protons. Where proton dilution could come into effect here is with 
the NPyr and NPF series as the polarisation transfer to the pyridyl groups are shared 
between four regions, whereas the NPOMe series has three. There will be an increase 
from 25% to 33% respectively. This could be a reason as to why the highest 
enhancements came from the NPOMe series.  
 
However, Mewis and co-workers researched the effect on random error when 
performing SABRE experiments.94 These factors included the shaking technique, the 
time taken to insert the Young’s tube into the NMR spectrometer and the time taken 
to initiate data collection using a software package. They followed up with saying the 
enhancement values here are more susceptible to error due to the significant changes 
in magnetic field during transfer to the magnet when contrasted to performing the 
same experiment but shaking the tube in earth’s magnetic field. A ±20% variation in 
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5 Final conclusion and future work 
This study initially looked at the successful synthesis of phenethylamines and 
NBOMe’s, by a range of synthetic techniques. By modifying the work up of the 
reduction reaction of the nitro-aldol to phenethylamine to include an acid–base wash, 
this significantly improved the purity of the compounds.  
  
A validated GC-MS method was developed for the detection and separation of eight 
NBOMe (49 - 55) derivatives within 11 minutes. All eight NBOMe’s were successfully 
separated with no co-eluting peaks and baseline resolution. LOD values ranged 
between 6.20 – 10.75 μg mL-1 and LOQ values ranged from 18.77 – 32.57 μg mL-1, 
which is low enough to effectively quantify the concentration of NBOMe within a blotter.  
  
25C-, 25B- and 25I-NBOMe were used, in separate instances, to simulate an 
impregnated blotter for analysis. ATR-FTIR and presumptive colour testing (Marquis 
and Leibermanns) could not be used confidently to identify the substances within the 
blotter. For ATR-FTIR, the amount of analyte was too low to be detected. For 
presumptive testing, the high acidity of the testing reagents tended to interact with the 
blotter paper, leading to leaching of the ink or staining on the blotter. Positive results 
were acquired after drug extraction of the blotters via GC-MS. There was a variation 
in success with the presumptive testing post extraction as 25C-NBOMe did not 
produce the colour output after extraction, but 25B- and 25I-NBOMe did. This was also 
the first documented case of Liebermann’s reagent being used to identify NBOMe’s, 
which can be applied in the case of the three NBOMe’s mentioned as they all differ in 
colour change. 
  
A library of 21 novel NBOMe derivatives were successfully synthesised, via reductive 
amination, with potential for being a replacement for PET imaging tracers. With all the 
characterisation completed, the data could be used as a presumptive library so that 
should these drugs emerge onto the black market, their detection and characterisation 
should be relatively facile. NBOMe derivatives possessing a pyridyl moiety (56 – 76), 
were subjected to SABRE. Hyperpolarised 1H and 19F NMR spectra were obtained. 
These compounds all displayed hyperpolarisation via SABRE, which could also be 
used as another rapid detection method, provided a facility were able to perform 
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SABRE-based experiments. 70 possessed the largest enhancement (192-fold) 
showing great promise in that it could replace the PET imaging agent cimbi-36 due to 
similarity in chemical structure. 
  
For future work, this would include performing in vivo biological assays with 25B-
NPOMe and 25I-NPOMe to show if there is an interaction with the 5-HT2A receptor. 
These two compounds are pertinent, due to the similarity of their radio labelled 
counterparts cimbi-5 and cimbi-36. However, this could also include the studies of 
another member of the research group, Nicolas Gilbert (PhD).169 This work focussed 
on the pyridyl derivatives of fentanyl, examples shown in Figure 38, which would also 
benefit from assay studies and bear structural similarity to the compounds synthesised 
herein.  
 
Such studies have been performed with the NBOMe derivatives, thus direct 
comparison of binding affinities can be applied and assessed. However, before 
embarking on this study, computational studies should be performed initially, to 
minimise costs associated with the synthesis and biological assays. With the crystal 
structure of serotonin receptor 5-HT2A being available, this could be prepared for 
docking and a faster method to determine which of the novel compounds would be the 
best fit. With the substitution of the methoxybenzyl for the methoxypyridyl group, an 
extra form of hydrogen bonding would be available, dependent on if there is a donating 
group provided on the protein backbone in close enough proximity. The presence of 
additional hydrogen bonding may increase binding affinity to the 5-HT2A receptor. This 
could lead into a computational project solely focusing on differing series of pyridyl 
drug derivatives.  
 
Hyperpolarisation of the pyridyl NBOMe’s is the first step to potentially unlocking how 
the 5-HT2A receptors function, however, further work is required for a biological 
compatible catalyst i.e. non-toxic and the ability to polarise the compound in-vivo. This 
could first be trialled by polarizing the samples with a biologically compatible solvent 
i.e. DMSO-d6. If this was to obtain a positive response similar to/or better than that 
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Due to only one 19F SABRE experiment being performed, there is a lot of scope fluoro 
hyperpolarization. The enhancement value of 63 would need to be larger to be 
considered for biological purpose. The current enhancement provides proof-of-
concept, as there are a number of ways to increase this value. Optimisation would 
include trialling different catalysts to perform polarisation transfer, utilisation of different 
solvents (with a focus on biological compatible solvents / mixtures), increasing the 
pressure of p-H2 and altering the magnetic field in which polarisation is conducted. 
One method to consider would be the use of a 19F SABRE in shield enables alignment 
transfer to heteronuclei (SHEATH) based experiment. These experiments utilise a 
micro-tesla field to conduct polarisation transfer in. Use of micro-tesla fields could 
improve polarisation transfer to 19F when compared to earth’s magnetic field, which 








1. R. Heim, Dissertation, Freie Universität Berlin 2004. 
2. D. A. Cahal, Brit. Med. J., 1974, 1, 70-72. 
3. Legislation.gov, Misuse of Drugs Act 1971, https://www.legislation.gov.uk/ukpga/1971/38/, 
Accessed 4 March 2017, 2017. 
4. U. Government, Drug penalties, https://www.gov.uk/penalties-drug-possession-dealing. 
5. Legislation.gov, The National Archives, Editon edn., 2001. 
6. Legislation.gov, The National Archives 
 Editon edn., 2005. 
7. B. V. Dean, S. J. Stellpflug, A. M. Burnett and K. M. Engebretsen, J. Med. Toxicol., 2013, 9, 172-
178. 
8. M. E. Nelson, S. M. Bryant and S. E. Aks, Disease a Month, 2014, 60, 110-132. 
9. D. S. Theobald, G. Fritschi and H. H. Maurer, J. Chromatogr. B Analyt. Technol. Biomed. Life 
Sci., 2007, 846, 374-377. 
10. D. d. Boer and I. Bosman, Pharm. World. Sci., 2004, 26, 110-113. 
11. J. L. Poklis, S. A. Raso, K. N. Alford, A. Poklis and M. R. Peace, J. Anal. Toxicol., 2015, 39, 617-
623. 
12. D. E. Administration, Federal register, 2013, 78, 68716. 
13. S. J. Stellpflug, S. E. Kealey, C. B. Hegarty and G. C. Janis, J. Med. Toxicol., 2014, 10, 45-50. 
14. D. Zuba and K. Sekuła, Drug Test. Anal., 2013, 5, 634-645. 
15. D. Zuba, K. Sekula and A. Buczek, Forensic Sci. Int., 2013, 227, 7-14. 
16. K. Sekuła and D. Zuba, Rapid Commun. Mass Spectrom., 2013, 27, 2081-2090. 
17. T. S. Krebs and P. O. Johansen, J. Psychopharmacol., 2012, 26, 994-1002. 
18. F. X. Vollenweider, M. F. I. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel and D. Hell, 
Neuroreport, 1998, 9, 3897-3902. 
19. K. H. Adams, E. S. Hansen, L. H. Pinborg, S. G. Hasselbalch, C. Svarer, S. Holm, T. G. Bolwig and 
G. M. Knudsen, Int. J. Neuropsychopharmacol., 2005, 8, 391-401. 
20. F. A. Moreno, C. B. Wiegand, E. K. Taitano and P. L. Delgado, J. Clin. Psychiatry, 2006, 67, 1735-
1740. 
21. P. Celada, V. M. Puig, M. Amargós-Bosch, A. Adell and F. Artigas, J. Psychiatry Neurosci., 2004, 
29, 252. 
22. R. L. Carhart-Harris, D. Erritzoe, T. Williams, J. M. Stone, L. J. Reed, A. Colasanti, R. J. Tyacke, 
R. Leech, A. L. Malizia and K. Murphy, Proc. Natl. Acad. Sci., 2012, 109, 2138-2143. 
23. K. Okamoto, H. Imbe, A. Kimura, T. Donishi, Y. Tamai and E. Senba, Neuroscience, 2007, 147, 
1090-1102. 
24. F. Nau Jr, B. Yu, D. Martin and C. D. Nichols, PloS one, 2013, 8, e75426. 
25. E. Hamel, Cephalalgia, 2007, 27, 1293-1300. 
26. R. A. Sewell, J. H. Halpern and H. G. Pope, Neurology, 2006, 66, 1920-1922. 
27. R. R. Griffiths, W. A. Richards, U. McCann and R. Jesse, Psychopharmacology, 2006, 187, 268-
283. 
28. D. L. Nelson, V. L. Lucates, D. B. Wainscott and R. A. Glennon, Naunyn-Schmiedeberg's Arch. 
Pharmacol., 1999, 359, 1-6. 
29. A. L. Halberstadt and M. A. Geyer, Neuropharmacology, 2014, 77, 200-207. 
30. A. T. Caspar, S. D. Brandt, A. E. Stoever, M. R. Meyer and H. H. Maurer, J. Pharm. Biomed. 
Anal., 2017, 134, 158-169. 
31. J. Suzuki, M. A. Dekker, E. S. Valenti, F. A. Arbelo Cruz, A. M. Correa, J. L. Poklis and A. Poklis, 
Psychosomatics, 2015, 56, 129-139. 




185 | P a g e  
 
33. M. Hansen, University of Copenhagen, 2010. 
34. M. E. Silva, R. Heim, A. Strasser, S. Elz and S. Dove, J. Comput. Aided Mol. Des., 2011, 25, 51-
66. 
35. C. Tirapegui, M. A. Toro-Sazo and B. K. Cassels, J. Chil. Chem. Soc., 2014, 59, 2625-2627. 
36. C. J. Pimentel Barros, Z. Cardosa De Souza, J. J. Rufino De Freitas, P. B. Norberto Da Silva, G. C. 
Gadelha Militao, T. Goncalves Da Silva, J. C. Rufino Freitas and J. Rufino De Freitas Filho, J. Chil. 
Chem. Soc., 2014, 59, 2359-2362. 
37. M. Hansen, K. Phonekeo, J. S. Paine, S. Leth-Petersen, M. Begtrup, H. Brauner-Osborne and J. 
L. Kristensen, ACS Chem. Neurosci., 2014, 5, 243-249. 
38. G. Klopman and O. T. Macina, J. Theor. Biol., 1985, 113, 637-648. 
39. M. Thakur, A. Thakur and P. V. Khadikar, Bioorg. Med. Chem., 2004, 12, 825-831. 
40. K. Neuvonen, H. Neuvonen and F. Fülöp, Bioorganic Med. Chem. Lett., 2006, 16, 3495-3498. 
41. M. R. Braden, Citeseer, 2007. 
42. A. Ettrup, M. Hansen, M. A. Santini, J. Paine, N. Gillings, M. Palner, S. Lehel, M. M. Herth, J. 
Madsen and J. Kristensen, European journal of nuclear medicine and molecular imaging, 2011, 
38, 681-693. 
43. A. Ettrup, M. Hansen, M. A. Santini, J. Paine, N. Gillings, M. Palner, S. Lehel, M. M. Herth, J. 
Madsen, J. Kristensen, M. Begtrup and G. M. Knudsen, Eur. J. Nucl. Med. Mol. Imaging, 2011, 
38, 681-693. 
44. V. B. Kueppers and C. T. Cooke, Forensic Sci. Int., 2015, 249, e15-18. 
45. D. B. Kitchen, H. Decornez, J. R. Furr and J. Bajorath, Nat. Rev. Drug Discov., 2004, 3, 935-949. 
46. N. Brooijmans and I. D. Kuntz, Annu. Rev. Biophys. Biomol. Struct., 2003, 32, 335-373. 
47. K.-Y. Tseng and M. Atzori, Monoaminergic modulation of cortical excitability, Springer, 2007. 
48. J. Cheng, P. M. Giguère, O. K. Onajole, W. Lv, A. Gaisin, H. Gunosewoyo, C. M. Schmerberg, V. 
M. Pogorelov, R. M. Rodriguiz and G. Vistoli, J. Med. Chem., 2015, 58, 1992-2002. 
49. V. Beliveau, M. Ganz, L. Feng, B. Ozenne, L. Højgaard, P. M. Fisher, C. Svarer, D. N. Greve and 
G. M. Knudsen, J. Neurosci., 2017, 37, 120-128. 
50. E. A. Engleman, Z. A. Rodd, R. L. Bell and J. M. Murphy, CNS Neurol. Disord. Drug Targets, 2008, 
7, 454-467. 
51. C. Wang, Y. Jiang, J. Ma, H. Wu, D. Wacker, V. Katritch, G. W. Han, W. Liu, X. P. Huang and E. 
Vardy, Science, 2013, 340, 610-614. 
52. D. Wacker, C. Wang, V. Katritch, G. W. Han, X. P. Huang, E. Vardy, J. D. McCorvy, Y. Jiang, M. 
Chu, F. Y. Siu, W. Liu, H. E. Xu, V. Cherezov, B. L. Roth and R. C. Stevens, Science, 2013, 340, 
615-619. 
53. Y. Q. Wang, W. W. Lin, N. Wu, S. Y. Wang, M. Z. Chen, Z. H. Lin, X. Q. Xie and Z. W. Feng, Acta 
Pharmacol. Sin., 2019, 40, 1138-1156. 
54. J. Z. Chen, J. Wang and X. Q. Xie, J. Chem. Inf. Model., 2007, 47, 1626-1637. 
55. Z. Feng, M. H. Alqarni, P. Yang, Q. Tong, A. Chowdhury, L. Wang and X. Q. Xie, J. Chem. Inf. 
Model., 2014, 54, 2483-2499. 
56. Z. Feng, S. Kochanek, D. Close, L. Wang, A. Srinivasan, A. A. Almehizia, P. Iyer, X. Q. Xie, P. A. 
Johnston and B. Gold, J. Chem. Biol., 2015, 8, 79-93. 
57. Z. Feng, L. V. Pearce, X. Xu, X. Yang, P. Yang, P. M. Blumberg and X. Q. Xie, J. Chem. Inf. Model., 
2015, 55, 572-588. 
58. K. Pfleger, H. H. Maurer and A. Weber, Mass spectral and GC data of drugs, poisons, pesticides, 
pollutants and their metabolites. Part 1: methods, tables, indexes, Wiley-VCH, Weinheim, 
2007. 
59. Y. Boumrah, L. Humbert, M. Phanithavong, K. Khimeche, A. Dahmani and D. Allorge, Drug. 
Test. Anal., 2016, 8, 248-256. 
60. A. T. Caspar, A. G. Helfer, J. A. Michely, V. Auwarter, S. D. Brandt, M. R. Meyer and H. H. 
Maurer, Anal Bioanal Chem, 2015, 407, 6697-6719. 
 
 
186 | P a g e  
 
61. D. E. Nichols, S. P. Frescas, B. R. Chemel, K. S. Rehder, D. Zhong and A. H. Lewin, Bioorg. Med. 
Chem., 2008, 16, 6116-6123. 
62. P. Nikolaou, I. Papoutsis, M. Stefanidou, C. Spiliopoulou and S. Athanaselis, Drug Chem. 
Toxicol., 2015, 38, 113-119. 
63. L. K. Laskowski, F. Elbakoush, J. Calvo, G. Exantus-Bernard, J. Fong, J. L. Poklis, A. Poklis and L. 
S. Nelson, J. Med. Toxicol., 2015, 11, 237-241. 
64. A. Al-Imam, Iran. J. Psychiatry Behav. Sci., 2018, 12. 
65. H. M. Elbardisy, C. W. Foster, J. Marron, R. E. Mewis, O. B. Sutcliffe, T. S. Belal, W. Talaat, H. G. 
Daabees and C. E. Banks, ACS Omega, 2019, 4, 14439-14450. 
66. B. Duffau, C. Camargo, M. Kogan, E. Fuentes and B. K. Cassels, J. Chromatogr. Sci., 2016, 54, 
1153-1158. 
67. C. Kyriakou, E. Marinelli, P. Frati, A. Santurro, M. Afxentiou, S. Zaami and F. P. Busardo, Eur. 
Rev. Med. Pharmacol. Sci., 2015, 19, 3270-3281. 
68. J. Coelho Neto, Forensic. Sci. Int., 2015, 252, 87-92. 
69. K. G. Shanks, T. Sozio and G. S. Behonick, J. Anal. Toxicol., 2015, 39, 602-606. 
70. A. M. d. Moreira, H. L. de Oliveira, J. F. Allochio Filho, D. H. A. Florez, M. M. C. Borges, V. 
Lacerda, W. Romão and K. B. Borges, Trend Anal. Chem., 2019, 114, 260-277. 
71. R. D. Johnson, S. R. Botch-Jones, T. Flowers and C. A. Lewis, J. Anal. Toxicol., 2014, 38, 479-
484. 
72. N. Uchiyama, Y. Shimokawa, S. Matsuda, M. Kawamura, R. Kikura-Hanajiri and Y. Goda, 
Forensic Toxicol., 2014, 32, 105-115. 
73. S. L. Hill, T. Doris, S. Gurung, S. Katebe, A. Lomas, M. Dunn, P. Blain and S. H. L. Thomas, Clin. 
Toxicol., 2013, 51, 487-492. 
74. S. R. Rose, J. L. Poklis and A. Poklis, Clin. Toxicol., 2013, 51, 174-177. 
75. J. L. Poklis, C. R. Nanco, M. M. Troendle, C. E. Wolf and A. Poklis, Drug Test. Anal., 2014, 6, 764-
769. 
76. J. L. Poklis, D. J. Clay and A. Poklis, J. Anal. Toxicol., 2014, 38, 113-121. 
77. J. L. Poklis, K. G. Devers, E. F. Arbefeville, J. M. Pearson, E. Houston and A. Poklis, Forensic Sci. 
Int., 2014, 234, e14-e20. 
78. K. Yoshida, K. Saka, K. Shintani-Ishida, H. Maeda, M. Nakajima, S. Hara, M. Ueno, K. Sasaki, H. 
Iwase and T. Sakamoto, Forensic Toxicol., 2015, 33, 396-401. 
79. M. Andreasen, F., R. Telving, I. Rosendal, M. B. Eg, J. Hasselstrøm, B. and L. V. Andersen, 
Forensic Sci. Int., 2015, 251, e1-e8. 
80. J. J. Kristofic, J. D. Chmiel, G. F. Jackson, S. P. Vorce, J. M. Holler, S. L. Robinson and T. Z. Bosy, 
J. Anal. Chem., 2016, 40, 466-472. 
81. J. P. Walterscheid, G. T. Phillips, A. E. Lopez, M. L. Gonsoulin, H. H. Chen and L. A. Sanchez, Am. 
J. Forensic Med. Pathol., 2014, 35, 20-25. 
82. J. L. Poklis, J. Charles, C. E. Wolf and A. Poklis, Biomed. Chromatogr., 2013, 27, 1794-1800. 
83. K. B. Borges, E. F. Freire, I. Martins and M. de Siqueira, E. P. B., Talanta, 2009, 78, 233-241. 
84. L. Nováková and H. Vlčková, Anal. Chim. Acta, 2009, 656, 8-35. 
85. P. Nikolaou, A. M. Coffey, M. J. Barlow, M. S. Rosen, B. M. Goodson and E. Y. Chekmenev, Anal. 
Chem., 2014, 86, 8206-8212. 
86. B. M. Goodson, N. Whiting, A. M. Coffey, P. Nikolaou, F. Shi, B. M. Gust, M. E. Gemeinhardt, 
R. V. Shchepin, J. G. Skinner and J. R. Birchall, eMagRes, 2007, 797-810. 
87. M. L. Hirsch, N. Kalechofsky, A. Belzer, M. Rosay and J. G. Kempf, J. Am. Chem. Soc., 2015, 137, 
8428-8434. 
88. T. Walker and W. Happer, 1997. 
89. J. H. Ardenkjær-Larsen, B. Fridlund, A. Gram, G. Hansson, L. Hansson, M. H. Lerche, R. Servin, 
M. Thaning and K. Golman, Proc. Natl. Acad. Sci., 2003, 100, 10158-10163. 




187 | P a g e  
 
91. K. H. Mok and P. J. Hore, Methods, 2004, 34, 75-87. 
92. C. R. Bowers and D. P. Weitekamp, Phys. Rev. Lett., 1986, 57, 2645-2648. 
93. R. W. Adams, J. A. Aguilar, K. D. Atkinson, M. J. Cowley, P. I. Elliott, S. B. Duckett, G. G. Green, 
I. G. Khazal, J. López-Serrano and D. C. Williamson, Science, 2009, 323, 1708-1711. 
94. R. E. Mewis, Magn. Reson. Chem., 2015, 53, 789-800. 
95. M. J. Cowley, R. W. Adams, K. D. Atkinson, M. C. Cockett, S. B. Duckett, G. G. Green, J. A. 
Lohman, R. Kerssebaum, D. Kilgour and R. E. Mewis, J. Am. Chem. Soc., 2011, 133, 6134-6137. 
96. M. Fekete, C. Gibard, G. J. Dear, G. G. Green, A. J. Hooper, A. D. Roberts, F. Cisnetti and S. B. 
Duckett, Dalton Trans., 2015, 44, 7870-7880. 
97. A. Manoharan, P. J. Rayner, W. Iali, M. J. Burns, V. H. Perry and S. B. Duckett, ChemMedChem, 
2018, 13, 352-359. 
98. A. N. Pravdivtsev, A. V. Yurkovskaya, H. Zimmermann, H. M. Vieth and K. L. Ivanov, RSC 
Advances, 2015, 5, 63615-63623. 
99. T. B. R. Robertson, L. H. Antonides, N. Gilbert, S. L. Benjamin, S. K. Langley, L. J. Munro, O. B. 
Sutcliffe and R. E. Mewis, ChemistryOpen, 2019, 8, 1375-1382. 
100. T. Tennant, M. C. Hulme, T. B. R. Robertson, O. B. Sutcliffe and R. E. Mewis, Magn. Reson. 
Chem., 2020. 
101. K. D. Atkinson, M. J. Cowley, S. B. Duckett, P. I. P. Elliott, G. G. Green, J. Lopez-Serrano, I. G. 
Khazal and A. C. Whitwood, Inorg. Chem., 2009, 48, 663-670. 
102. R. W. Adams, J. A. Aguilar, K. D. Atkinson, M. J. Cowley, P. I. P. Elliott, S. B. Duckett, G. G. R. 
Green, I. G. Khazal, J. Lopez-Serrano and W. D. C., Science, 2009, 323, 1708-1711. 
103. P. M. Richardson, A. J. Parrott, O. Semenova, A. Nordon, S. B. Duckett and M. E. Halse, Analyst, 
2018, 143, 3442-3450. 
104. J. J. Vaquero and P. Kinahan, Annu. Rev. Biomed. Eng., 2015, 17, 385-414. 
105. G. T. Gullberg, G. L. Zeng, F. L. Datz, P. E. Christian, C. H. Tung and H. T. Morgan, Phys. Med. 
Biol., 1992, 37, 507. 
106. S. Geethanath and J. T. Vaughan, Jr., J. Magn. Reson. Imaging, 2019, 49, e65-e77. 
107. E. Kaplan, A. K. Prashanth, C. Brennan and L. Sirovich, Optics and Photonics News, 2000, 11, 
26. 
108. T. C. Kwee, D. A. Torigian and A. Alavi, J. Thorac. Imaging, 2013, 28, 1-10. 
109. S. J. Finnema, V. Stepanov, A. Ettrup, R. Nakao, N. Amini, M. Svedberg, C. Lehmann, M. Hansen, 
G. M. Knudsen and C. Halldin, Neuroimage., 2014, 84, 342-353. 
110. L. W. Fitzgerald, D. S. Conklin, C. M. Krause, A. P. Marshall, J. P. Patterson, D. P. Tran, G. Iyer, 
W. A. Kostich, B. L. Largent and P. R. Hartig, J. Neurochem., 1999, 72, 2127-2213. 
111. A. Ettrup, M. Palner, N. Gillings, M. A. Santini, M. Hansen, B. R. Kornum, L. K. Rasmussen, K. 
Nagren, J. Madsen, M. Begtrup and G. M. Knudsen, J. Nucl. Med., 2010, 51, 1763-1770. 
112. B. Biver, S. Goldman, A. Leuxen, M. Monclus, M. Forestini, J. Mendlewicz and F. Lotstra, Eur. 
J. Nuc. Med., 1994, 21, 937-946. 
113. H. Ito, S. Nyberg, C. Halldin, C. Lundkvist and F. L., J. Nucl. Med., 1998, 39, 208-214. 
114. L. H. Pinborg, K. H. Adams, S. Yndgaard, S. G. Hasselbalch, S. Holm, H. Kristiansen, O. B. Paulson 
and G. M. Knudsen, J. Cereb. Blood. Flow Metab., 2004, 24, 1037-1045. 
115. D. Hoyer, J. P. Hannon and G. R. Martin, Pharmacol. Biochem. Behav., 2002, 71, 533-554. 
116. B. J. Jones and T. P. Blackburn, Pharmacol. Biochem. Behav., 2002, 71. 
117. N. M. Barnes and T. Sharp, Neuropharmacology, 1999, 38, 1083-1152. 
118. D. Hoyer, D. E. Clarke, J. R. Fozard, P. R. Hartig, G. R. Martin, E. J. Mylecharane, P. R. Saxena 
and P. P. A. Humphrey, Pharmacol. Rev., 1994, 46, 157-203. 
119. F. G. Boess and I. L. Martin, Neuropharmacology, 1994, 33, 275-317. 
120. G. V. Williams, S. G. Rao and P. S. Goldman-Rakic, J. Neurosci., 2002, 22, 2843-2854. 
121. J. A. Harvey, Learn. Mem., 2003, 10, 355-362. 
122. J. E. Leyson, D. de Chaffoy de Courcelles, F. de Clerck, C. J. E. Niemegeers and J. M. Van nueton, 
Neuropharmacology, 1984, 23, 1493-1501. 
 
 
188 | P a g e  
 
123. A. R. Blaazer, P. Smid and C. G. Kruse, ChemMedChem, 2008, 3, 1299-1309. 
124. R. Narendran, D. R. Hwang, M. Slifstein, Y. Hwang, Y. Huang, J. Ekelund, O. Guillin, E. Scher, D. 
Martinez and M. Laruelle, J. Pharmacol. Exp. Ther., 2005, 315, 80-90. 
125. R. Narendran, S. Mason, C. Laymon, B. Lopresti, N. Velasquez, M. May, S. Kendro, D. Martinez, 
C. Mathis and G. Frankle, J. Pharmacol. Exp. Ther., 2010, 371. 
126. D. Martinez and R. Narendran, in Behavioral Neuroscience of Drug Addiction, eds. D. W. Self 
and J. K. Staley Gottschalk, Springer Berlin Heidelberg, Berlin, Heidelberg, Editon edn., 2010, 
vol. 3, pp. 219-245. 
127. A. Ettrup, S. Holm, M. Hansen, M. Wasim, M. A. Santini, M. Palner, J. Madsen, C. Svarer, J. L. 
Kristensen and G. M. Knudsen, Mol. Imaging Biol., 2013, 15, 376-383. 
128. S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, Chem. Soc. Rev., 2008, 37, 320-330. 
129. Rapid Testing Methods of Drugs of Abuse, 
https://www.unodc.org/documents/scientific/Rapid_Testing_Methods_of_Drugs_of_Abuse
_E.pdf. 
130. O. Torres, M. Martin and E. Sola, Organometallics, 2009, 28, 863-870. 
131. A. M. Olaru, T. B. R. Robertson, J. S. Lewis, A. Anthony, W. Lali, R. E. Mewis and S. B. Duckett, 
ChemistryOpen, 2018, 7, 97-105. 
132. T. Kanamori, H. Inoue, Y. Iwata, Y. Ohmae and T. Kishi, J. Anal. Toxicol., 2002, 26, 61-66. 
133. B. J. D. Wright, J. Hartung, F. Peng, R. Water, H. Liu, Q. Tan, T. Chou and S. J. Danishefsky, J. 
Am. Chem. Soc., 2008, 130, 16786-16790. 
134. J. L. Bloomer, K. W. Stagliano and J. A. Gazzillo, J. Org. Chem., 1993, 58, 7906-7912. 
135. A. Miyawaki, D. Kikuchi, M. Niki, Y. Manabe, M. Kanematsu, H. Yokoe, M. Yoshida and K. 
Shishido, J. Org. Chem., 2012, 77, 8231-8243. 
136. H. Sharghi, M. Jokar, M. M. Doroodmand and R. Khalifeh, Adv. Synth. Catal., 2010, 352, 3031-
3044. 
137. Y. Saito, A. Mizokami, H. Tsurimoto, K. Izumi, M. Goto and K. Nakagawa-Goto, Eur. J. Med. 
Chem., 2018, 157, 1143-1152. 
138. W. P. Roberts and C. L. Ebner, J. Org. Chem., 1987, 52, 2297-2299. 
139. B. Wang, H. X. Sun, Z. H. Sun and G. Q. Lin, Adv. Synth. Catal., 2009, 351, 415-422. 
140. A. T. Shulgin and D. C. Dyer, J. Med. Chem., 1975, 18, 1201-1204. 
141. R. A. Glennon, R. Young, F. Benington and R. D. Morin, J. Med. Chem., 1982, 25, 1163-1168. 
142. M. Hansen, K. Phonekeo, J. S. Paine, S. Leth-Petersen, M. Begtrup, H. Bräuner-Osborne and J. 
L. Kristensen, ACS Chem. Neurosci., 2014, 5, 243-249. 
143. A. T. Shulgin and A. Shulgin, PIHKAL - A Chemical Love Story, Transform Press, USA, 1991. 
144. Huang-Minlon, J. Am. Chem. Soc., 1946, 68, 2487-2488. 
145. S. A. Kaliyaperumal, S. Banerjee and K. S. U, Org. Biomol. Chem., 2014, 12, 6105-6113. 
146. J. W. Baker and H. B. Hopkins, J. Chem. Soc., 1949, 0, 1089-1097. 
147. S. Siddiqui, S. Kadlecek, M. Pourfathi, Y. Xin, W. Mannherz, H. Hamedani, N. Drachman, K. 
Ruppert, J. Clapp and R. Rizi, Adv. Drug Deliv. Rev., 2017, 113, 3-23. 
148. M. L. Truong, T. Theis, A. M. Coffey, R. V. Shchepin, K. W. Waddell, F. Shi, B. M. Goodson, W. 
S. Warren and E. Y. Chekmenev, J. Phys. Chem. C Nanomater Interfaces, 2015, 119, 8786-8797. 
149. R. V. Shchepin, B. M. Goodson, T. Theis, W. S. Warren and E. Y. Chekmenev, ChemPhysChem, 
2017, 18, 1961-1965. 
150. A. Abragam and M. Goldman, Rep. Prog. Phys., 1978, 41, 395-467. 
151. N. D. Bhaskar, W. Happer and T. McClellend, Phys. Rev. Lett., 1982, 49, 25-28. 
152. L. L. Walkup and J. C. Woods, NMR Biomed., 2014, 27, 1429-1438. 
153. J. M. Lupo, A. P. Chen, M. L. Zierhut, R. A. Bok, C. H. Cunningham, J. Kurhanewicz, D. B. 
Vigneron and S. J. Nelson, Magn. Reson. Imaging, 2010, 28, 153-162. 
154. J. Leonard, A. Haddad, O. Green, R. L. Birke, T. Kubic, A. Kocak and J. R. Lombardi, J. Raman 
Spectrosc., 2017, 48, 1323-1329. 
155. M. Schackmuth and S. Kerrigan, Forensic Toxicol., 2018, 37, 231-237. 
 
 
189 | P a g e  
 
156. K. E. Strayer, H. M. Antonides, M. P. Juhascik, R. Daniulaityte and I. E. Sizemore, ACS Omega, 
2018, 3, 514-523. 
157. H. M. Elbardisy, C. W. Foster, L. Cumba, L. H. Antonides, N. Gilbert, C. J. Schofield, T. S. Belal, 
W. Talaat, O. B. Sutcliffe, H. G. Daabees and C. E. Banks, Anal. Methods, 2019, 11, 1053-1063. 
158. N. Gilbert, L. H. Antonides, C. J. Schofield, A. Costello, B. Kilkelly, A. R. Cain, P. R. V. Dalziel, K. 
Horner, R. E. Mewis and O. B. Sutcliffe, Drug Test. Anal., 2020. 
159. J. Duffy, A. Urbas, M. Niemitz, K. Lippa and I. Marginean, Anal. Chim. Acta., 2019, 1049, 161-
169. 
160. F. Shi, A. M. Coffey, K. W. Waddell, E. Y. Chekmenev and B. M. Goodson, Angew Chem. Int. Ed. 
Engl., 2014, 53, 7495-7498. 
161. T. Theis, M. L. Truong, A. M. Coffey, R. V. Shchepin, K. W. Waddell, F. Shi, B. M. Goodson, W. 
S. Warren and E. Y. Chekmenev, J. Am. Chem. Soc., 2015, 137, 1404-1407. 
162. R. E. Mewis, K. D. Atkinson, M. J. Cowley, S. B. Duckett, G. G. Green, R. A. Green, L. A. Highton, 
D. Kilgour, L. S. Lloyd, J. A. Lohman and D. C. Williamson, Magn. Reson. Chem., 2014, 52, 358-
369. 
163. R. W. Adams, S. B. Duckett, R. A. Green, D. C. Williamson and G. G. Green, J. Chem. Phys., 2009, 
131, 194505. 
164. L. S. Lloyd, A. Asghar, M. J. Burns, A. Charlton, S. Coombes, M. J. Cowley, G. J. Dear, S. B. 
Duckett, G. R. Genov, G. G. Green, L. A. Highton, A. J. Hooper, M. Khan, I. G. Khazal, R. J. Lewis, 
R. E. Mewis, A. D. Roberts and A. J. Ruddleston, Cat. Sci. Technol., 2014, 4, 3544-3554. 
165. J. N. Shoolery, Prog. NMR Spec., 1995, 28, 37-52. 
166. R. E. Mewis, M. Fekete, G. G. Green, A. C. Whitwood and S. B. Duckett, Chem. Commun. 
(Camb), 2015, 51, 9857-9859. 
167. F. R. Jenson, C. H. Bushweller and B. H. Beck, J. Am. Chem. Soc., 1969, 91. 
168. H. J. Schneider and V. Hoppen, J. Org. Chem., 1978, 43. 
169. N. Gilbert, Manchester Metropolitan University, 2021. 
 
 
